




- (51) **International Patent Classification:**
C12N 15/113 (2010.01) *A61K 31/7105* (2006.01)
- (21) **International Application Number:**
PCT/IB2016/001169
- (22) **International Filing Date:**
26 July 2016 (26.07.2016)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/197,370 27 July 2015 (27.07.2015) US
- (71) **Applicant:** OLIX PHARMACEUTICALS, INC.
[KR/KR]; 60-11 Star Valley, Suite 1305, Gasan-dong,
Geumcheon-gu, Seoul 153-777 (KR).
- (72) **Inventors:** HONG, Sun, Woo; LG Village Apt., #211-
1905, Geumgok-ro, Gwonseon-gu, Suwon-si, Gyeonggi-do
45 (KR). HONG, Isu; SK HUB SU 27, Rm. 703, Guil-ro
10-gil, Seoul 27 (KR). KIM, Ji, Hyun; GreenM House,
Room 203, 4254 Singlil 6-dong, Seoul 4254 (KR).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: RNA COMPLEXES THAT INHIBIT MELANIN PRODUCTION

Figure 1



(57) **Abstract:** In certain aspects, provided herein are RNA complexes (e.g., asymmetric RNA complexes, such as asiRNAs and lasiRNAs) that inhibit tyrosinase expression and are therefore useful for reducing melanin production and for treating pigmentation-related disorders associated with excessive melanin production, such as melasma and age spots.



Published:

— *with international search report (Art. 21(3))*

RNA COMPLEXES THAT INHIBIT MELANIN PRODUCTION

RELATED APPLICATIONS

This application claims the benefit of U.S. provisional application 62/197,370, filed
5 July 27, 2015, which is hereby incorporated by reference in its entirety.

BACKGROUND

Excess melanin production by melanocytes is associated with a variety of skin
pigmentation-related disorders, including melasma and age spots. In melasma, excessive
production of melanin results in black deposits in melanocytes present in the epidermal skin
10 layer. Melasma is one of the leading refractory diseases occurring in the skin of women.
Melasma often occurs in pregnant women and in women who are taking oral or patch
contraceptives or undergoing hormone replacement therapy.

Tyrosinase is an oxidase that is the rate limiting enzyme in the synthesis of melanin
and is therefore an important therapeutic target for agents that reduce hyperpigmentation
15 and treat skin pigmentation-related disorders. In humans, the tyrosinase enzyme is encoded
by the TYR gene. Mutations in the TYR gene that result in impaired tyrosinase production
lead to type I oculocutaneous albinism.

Currently available treatments of skin pigmentation-related disorders associated
with excessive melanin production include hydroquinone, arbutin, tretinoin, azelaic acid,
20 kojic acid, chemical peels and microdermabrasion. However, such treatments are often
ineffective and can have significant side-effects. Individuals with such disorders often need
to resort to cosmetics to hide the areas of excessive skin pigmentation.

Thus, there is a need for improved compositions and methods for the inhibition of
melanin production and the treatment of skin pigmentation-related disorders, including
25 melasma and age spots.

SUMMARY

In certain aspects, provided herein are RNA complexes that inhibit tyrosinase and
are useful for reducing melanin production and the treatment of pigmentation-related
disorders, including melasma and age spots. In certain aspects, provided herein are
30 pharmaceutical compositions comprising such RNA complexes and methods of using such
RNA complexes and pharmaceutical compositions.

In certain aspects, provided herein is an RNA complex comprising an antisense
strand having sequence complementarity to a tyrosinase mRNA sequence (*e.g.*, a human

tyrosinase mRNA sequence) and a sense strand having sequence complementarity to the antisense strand. In some embodiments, the RNA complex is capable of inhibiting tyrosinase expression by a cell (*e.g.*, a melanocyte). In certain embodiments, the RNA complex is capable of inhibiting melanin production by a cell (*e.g.*, a melanocyte). In some
5 embodiments, the RNA complex is an asymmetric short interfering RNA (an asiRNA). In some embodiments, the RNA complex is a long asymmetric short interfering RNA (a lasiRNA). In some embodiments, the RNA complex is an RNA complex listed in Table 1, Table 2, Table 4, Table 5 and Table 6.

10 In some embodiments, the RNA complex provided herein comprises a chemical modification, wherein the modification facilitates the penetration of a cellular membrane in the absence of a delivery vehicle. In some embodiments, the modification is a 2'-O-methylated nucleoside, a phosphorothioate bond or a cholesterol moiety. In some embodiments, the RNA complex is a modified RNA complex listed in Table 2 or Table 4. In certain embodiments, the RNA complex is not cytotoxic.

15 In certain aspects, provided herein is a pharmaceutical composition comprising an RNA complex provided herein and a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition is formulated for topical delivery. In some embodiments, the pharmaceutical composition is a cream or a lotion. In some embodiments, the pharmaceutical composition further comprises a second skin lightening
20 agent (*e.g.*, hydroquinone, arbutin, tretinoin, kojic acid, azelaic acid or tranexamic acid).

25 In certain aspects, provided herein is a method of inhibiting tyrosinase expression by a cell (*e.g.*, a melanocyte) comprising contacting the cell with an RNA complex provided herein. In certain aspects, provided herein is a method of inhibiting melanin production by a cell (*e.g.*, a melanocyte) comprising contacting the cell with an RNA complex provided herein.

30 In certain aspects, provided herein is a method of inhibiting melanin production in the skin of a human subject comprising administering to the subject an RNA complex or pharmaceutical composition provided herein. In certain aspects, provided herein is a method of treating a human subject for a skin pigmentation disorder associated with excessive melanin production (*e.g.*, melasma or age spots) comprising administering to the subject an RNA complex or pharmaceutical composition provided herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the gene silencing efficiency of 62 exemplary asiRNAs that target tyrosinase. The asiRNAs were transfected in A375P at a concentration of 0.3 nM, and, after 24 hours, the degree of tyrosinase mRNA expression was measured using real-time PCR. The graph depicts the mean and standard deviation of three repeat experiments.

Figure 2 shows the gene silencing efficiency of exemplary tyrosinase-targeting cell penetrating asiRNAs (cp-asiRNAs, or cp-asiTYRs) to which various chemical modifications have been applied. The cp-asiRNAs were incubated without transfection vehicle in the presence of MNT-1 cells at a concentration of 1 μ M, and, after 48 hours, the degree of tyrosinase mRNA expression was measured using real-time PCR. The graph depicts the mean and standard deviation of three repeat experiments.

Figure 3 shows the inhibition of tyrosinase protein expression by exemplary cp-asiRNAs. The cp-asiRNAs were contacted with MNT-1 cells without transfection vehicle and, after 72 hours, proteins were extracted and a western blot was performed (NT = no treatment).

Figure 4 shows the result of a melanin content assay performed 72 hours after the treatment of MNT-1 cells with exemplary cp-asiRNAs without transfection vehicle (NT = no treatment).

Figure 5 shows pigmentation inhibition by exemplary cp-asiRNAs. Panel (a) depicts the color change of MNT-1 cells 72 hours after treatment with cp-asiRNA without transfection vehicle. Panel (b) depicts the color change of the melanin obtained from the MNT-1 cell line 72 hours after treatment of the MNT-1 cells with cp-asiRNA without vehicle (NT = no treatment).

Figure 6 shows the cytotoxicity of cells treated with exemplary cp-asiRNAs without transfection vehicle using a LDH assay and a CCK-8 assay. Panel (a) depicts the cytotoxicity in MNT-1 cells 24 hours after the treatment with the exemplary cp-asiRNAs or the indicated controls as determined by an LDH assay. Panel (b) depicts the cytotoxicity in MNT-1 cells 24 hours after the treatment with cp-asiRNAs or the indicated controls as determined by a CCK-8 assay. Panel (c) depicts the cytotoxicity in HaCaT cells 24 hours after treatment with cp-asiRNAs or controls as determined by an LDH assay. Panel (d) depicts the cytotoxicity of HaCaT cells 24 hours after treatment with cp-asiRNAs or controls as determined by a CCK-8 assay (NT = no treatment).

Figure 7 shows the gene silencing effects of exemplary cp-asiRNAs of different antisense strand lengths (21 or 19 nucleotides) and containing 2'-O-Methylation

modifications. Each cp-asiRNA was contacted to MNT-1 without transfection vehicle at 1 μ M concentration and the resulting tyrosinase mRNA production was measured by Real-Time PCR after 48 hours.

5 **Figure 8** shows the inhibition of tyrosinase protein expression by exemplary cp-asiRNAs. The indicated cp-asiRNAs were contacted to MNT-1 cells without transfection vehicle and, after 72 hours, proteins were extracted and a western blot was performed (NT = no treatment).

10 **Figure 9** shows the results produced by a melanin content assay performed 72 hours after the treatment of MNT-1 cells with exemplary cp-asiRNAs without transfection vehicle. (NT = no treatment).

Figure 10 shows the inhibition of tyrosinase protein expression by exemplary cp-asiRNAs. The indicated cp-asiRNAs were contacted to MNT-1 cells without transfection vehicle and, after 72 hours, proteins were extracted and a western blot was performed (NT = no treatment).

15 **Figure 11** shows the effect of treatment of MNT-1 cells with exemplary asiRNAs and lasiRNAs. Each complex identified was incubated with MNT-1 cells for 48 hours at the indicated concentration and tyrosinase mRNA expression was determined by real-time RT-PCR.

20 **Figure 12** shows the effect of treatment of MNT-1 cells with exemplary asiRNAs and lasiRNAs. Panel (a) depicts the results produced by a western blot for tyrosinase expression by MNT-1 cells 72 hours after the treatment with exemplary asiRNAs, lasiRNAs or controls. Panel (b) depicts the melanin content of MNT-1 cells 72 hours after treatment with exemplary asiRNAs, lasiRNAs or controls (NT = no treatment).

Figure 13 provides the human tyrosinase mRNA sequence.

25 **Figure 14** shows inhibition of melanin synthesis in reconstructed skin model by an exemplary cp-asiRNA. Panel (a) depicts the experimental scheme for the study in which cp-MEL-300-B samples were treated every day for 13 days with asiTYR#4-1 in medium (13 times). Panel (b) shows light microscopy analysis of melanocyte in a no treatment control sample (NT), a cp-asiTYR#4-1 treated sample, and a kojic acid treated sample. Panel (c)
30 shows Fontana-Massons staining for melanin analysis in a no treatment control sample (NT), a cp-asiTYR#4-1 treated sample, and a kojic acid treated sample. Panel (d) shows the tyrosinase mRNA level at day 14 as measured using real-time PCR. Panel (e) shows

tyrosinase protein level at day 14 as measured by western blot. Panel (f) shows the melanin content of samples at day 14 as measured using a melanin contents assay.

DETAILED DESCRIPTION

General

5 In certain aspects, provided herein are asymmetric RNA complexes (*e.g.*, asiRNAs or lasiRNAs) that inhibit tyrosinase expression and are therefore useful for reducing melanin production and the treatment of pigmentation-related disorders associated with excessive melanin production, such as melasma and age spots. In some embodiments, the RNA complexes are chemically modified to be capable of penetrating a cell without need
10 for a transfection vehicle. In some embodiments, the RNA complex is an RNA complex listed in Table 1, Table 2, Table 4, Table 5 and Table 6. In certain aspects, provided herein are pharmaceutical compositions comprising such RNA complexes and methods of using such RNA complexes and pharmaceutical compositions.

15 Tyrosinase is a protein that plays a key role in melanin synthesis. Various small molecule inhibitors targeting tyrosinase, including hydroquinone, retinoic acid and kojic acid, have been used as active ingredients of skin-whitening products. However, such treatments are often ineffective and often result in serious side effects, such as itching and skin browning.

In certain embodiments, the RNA complexes provided herein have reduced risk for
20 side effects compared to the conventional small molecules currently in use for skin whitening. As described herein, exemplary RNA complexes provided herein have significant tyrosinase inhibitory effect, even at a 1000-fold lower concentration than current skin-whitening agents. Thus, the RNA complexes provided herein can replace or supplement currently available small molecule products for improved skin-whitening
25 effects.

In some embodiments, the RNA complexes described herein are asiRNAs or lasiRNAs. As used herein, the term asiRNA refers to double-stranded asymmetrical short interfering RNA molecules that have a 19-21 nt antisense strand and a 13-17 nt sense strand. Additional information on asiRNAs can be found in U.S. Pat. Pub. No.
30 2012/0238017 and in Chang *et al.*, *Mol. Ther.* 17:725-732 (2009), each of which is hereby incorporated by reference in its entirety. As used herein, the term lasiRNA refers to double-stranded long asymmetrical interfering RNA molecules that have a 13-21 nt sense strand and an antisense strand of greater than 24 nt. Additional information on lasiRNAs can be

found in U.S. Pat. Pub. No. 2013/0273657, which is hereby incorporated by reference in its entirety.

In some embodiments, the RNA complexes described herein are delivered to cells using a delivery vehicle, such as liposomes, cationic polymers, cell penetrating peptides (CPPs), protein transduction domains (PTDs), antibodies and/or aptamers. In some
5 embodiments, the RNA complex described herein is chemically modified so as to not require the use of such delivery vehicles to mediate tyrosinase inhibition in a cell. Such RNA complexes are referred to herein as cell-penetrating asiRNAs (cp-asiRNAs) or cell-penetrating lasiRNAs (cp-lasiRNAs).

10 Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

The articles “*a*” and “*an*” are used herein to refer to one or to more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, “an element”
15 means one element or more than one element.

As used herein, the term “*administering*” means providing a pharmaceutical agent or composition to a subject, and includes, but is not limited to, administering by a medical professional and self-administering.

As used herein, the terms “*interfering nucleic acid*,” “*inhibiting nucleic acid*” are
20 used interchangeably. Interfering nucleic acids generally include a sequence of cyclic subunits, each bearing a base-pairing moiety, linked by intersubunit linkages that allow the base-pairing moieties to hybridize to a target sequence in a nucleic acid (typically an RNA) by Watson-Crick base pairing, to form a nucleic acid:oligomer heteroduplex within the target sequence. Interfering RNA molecules include, but are not limited to, antisense
25 molecules, siRNA molecules, asiRNA molecules, lasiRNA molecules, single-stranded siRNA molecules, miRNA molecules and shRNA molecules. Such an interfering nucleic acids can be designed to block or inhibit translation of mRNA or to inhibit natural pre-mRNA splice processing, or induce degradation of targeted mRNAs, and may be said to be “directed to” or “targeted against” a target sequence with which it hybridizes. Interfering
30 nucleic acids may include, for example, peptide nucleic acids (PNAs), locked nucleic acids (LNAs), 2'-O-Methyl oligonucleotides and RNA interference agents (siRNA agents). RNAi molecules generally act by forming a heteroduplex with the target molecule, which is selectively degraded or “knocked down,” hence inactivating the target RNA. Under some

conditions, an interfering RNA molecule can also inactivate a target transcript by repressing transcript translation and/or inhibiting transcription of the transcript. An interfering nucleic acid is more generally said to be “targeted against” a biologically relevant target, such as a protein, when it is targeted against the nucleic acid of the target in the manner described above.

The terms “*polynucleotide*”, and “*nucleic acid*” are used interchangeably. They refer to a polymeric form of nucleotides, whether deoxyribonucleotides, ribonucleotides, or analogs thereof, in any combination and of any length. Polynucleotides may have any three-dimensional structure, and may perform any function. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. A polynucleotide may be further modified, such as by conjugation with a labeling component. In all nucleic acid sequences provided herein, U nucleotides are interchangeable with T nucleotides.

The phrase “*pharmaceutically-acceptable carrier*” as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material.

An oligonucleotide “*specifically hybridizes*” to a target polynucleotide if the oligomer hybridizes to the target under physiological conditions, with a T_m substantially greater than 45° C, or at least 50° C, or at least 60° C-80° C or higher. Such hybridization corresponds to stringent hybridization conditions. At a given ionic strength and pH, the T_m is the temperature at which 50% of a target sequence hybridizes to a complementary polynucleotide. Again, such hybridization may occur with “near” or “substantial” complementarity of the antisense oligomer to the target sequence, as well as with exact complementarity.

As used herein, the term “*subject*” means a human or non-human animal selected for treatment or therapy.

The phrases "*therapeutically-effective amount*" and "*effective amount*" as used herein means the amount of an agent which is effective for producing the desired therapeutic effect in at least a sub-population of cells in a subject at a reasonable benefit/risk ratio applicable to any medical treatment.

- 5 "*Treating*" a disease in a subject or "*treating*" a subject having a disease refers to subjecting the subject to a pharmaceutical treatment, *e.g.*, the administration of a drug, such that at least one symptom of the disease is decreased or prevented from worsening.

RNA Complexes

- 10 In certain aspects, provided herein are RNA complexes that target tyrosinase mRNA and inhibit tyrosinase expression by a cell. Tyrosinase is an oxidase that is the rate-limiting enzyme for controlling production of melanin. The nucleic acid sequence of human tyrosinase mRNA is available at NCBI accession numbers NM_000372 and is provided in Figure 13.

- 15 In certain aspects, provided herein is an RNA complex comprising an antisense strand having sequence complementarity to a tyrosinase mRNA sequence (*e.g.*, a human tyrosinase mRNA sequence) and a sense strand having sequence complementarity to the antisense strand. In some embodiments, the RNA complex is capable of inhibiting tyrosinase expression by a cell (*e.g.*, a melanocyte). In certain embodiments, the RNA complex is capable of inhibiting melanin production by a cell (*e.g.*, a melanocyte). In some
20 embodiments, the RNA complex is an asymmetric short interfering RNA (an asiRNA). In some embodiments, the RNA complex is a long asymmetric short interfering RNA (a lasiRNA). In some embodiments, the RNA complex is an RNA complex listed in Table 1, Table 2, Table 4, Table 5 and Table 6. The RNA complexes described herein can contain RNA bases, non-RNA bases or a mixture of RNA bases and non-RNA bases. For example,
25 certain RNA complexes provided herein can be primarily composed of RNA bases but also contain DNA bases or non-naturally occurring nucleotides.

- In some embodiments, the antisense strand is at least 19 nucleotides (nt) in length. In some embodiments, the antisense strand is 19 to 21 nt in length (*i.e.*, 19, 20 or 21 nt in length). In some embodiments, at least 13, 14, 15, 16, 17, 18, 19, 20 or 21 nt of the
30 antisense strand are complementary to the tyrosinase mRNA sequence. Perfect complementarity is not necessary. In some embodiments, the antisense strand is perfectly complementary to the tyrosinase mRNA sequence.

In some embodiments, the antisense strand is at least 24 nt in length (*e.g.*, at least 25 nt in length, at least 26 nt in length, at least 27 nt in length, at least 28 nt in length, at least 29 nt in length, at least 30 nt in length or at least 31 nt in length). In some embodiments, the antisense strand is no greater than 124 nt in length (*e.g.*, no greater than 100 nt in length, no greater than 90 nt in length, no greater than 80 nt in length, no greater than 70 nt in length, no greater than 60 nt in length, no greater than 50 nt in length or no greater than 40 nt in length). In some embodiments, the antisense strand is 31 nt in length. In some embodiments, at least 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 29, 30 or 31 nt of the antisense strand are complementary to the tyrosinase mRNA sequence. Perfect complementarity is not necessary. In some embodiments, the antisense strand is perfectly complementary to the tyrosinase mRNA sequence.

In some embodiments, the sense strand is 15 to 17 nt in length (*i.e.*, 15 nt in length, 16 nt in length or 17 nt in length). In some embodiments, at least 15 nt, at least 16 nt or at least 17 nt of the sense strand are complementary to the sequence of the antisense strand. In some embodiments the sense strand is perfectly complementary to the sequence of the antisense strand.

In some embodiments, the antisense strand and the sense strand form a complex in which the 5' end of the antisense strand and the 3' end of the sense strand form a blunt end. In some embodiments, the antisense strand and the sense strand form a complex in which the 5' end of the antisense strand overhangs the 3' end of the sense strand (*e.g.*, by 1, 2, 3, 4 or 5 nt). In some embodiments, the antisense strand and the sense strand form a complex in which the 5' end of the sense strand overhangs the 3' end of the antisense strand (*e.g.*, by 1, 2, 3, 4 or 5 nt).

In some embodiments, the antisense strand and/or the sense strand of the RNA complex has a sense strand sequence and/or an antisense strand sequence selected from the sequences listed in Table 1, Table 2, Table 4, Table 5 and Table 6. In some embodiments, the sense strand has a sequence of SEQ ID NO: 1 and the antisense strand has a sequence of SEQ ID NO: 2. In some embodiments, the sense strand has a sequence of SEQ ID NO: 3 and the antisense strand has a sequence of SEQ ID NO: 4. In some embodiments, the sense strand has a sequence of SEQ ID NO: 5 and the antisense strand has a sequence of SEQ ID NO: 6. In some embodiments, the sense strand has a sequence of SEQ ID NO: 7 and the antisense strand has a sequence of SEQ ID NO: 8. In some embodiments, the sense strand has a sequence of SEQ ID NO: 9 and the antisense strand has a sequence of SEQ ID NO:

[illegible]

[illegible]

98. In some embodiments, the sense strand has a sequence of SEQ ID NO: 99 and the antisense strand has a sequence of SEQ ID NO: 100. In some embodiments, the sense strand has a sequence of SEQ ID NO: 101 and the antisense strand has a sequence of SEQ ID NO: 102. In some embodiments, the sense strand has a sequence of SEQ ID NO: 103 and the antisense strand has a sequence of SEQ ID NO: 104. In some embodiments, the sense strand has a sequence of SEQ ID NO: 105 and the antisense strand has a sequence of SEQ ID NO: 106. In some embodiments, the sense strand has a sequence of SEQ ID NO: 107 and the antisense strand has a sequence of SEQ ID NO: 108. In some embodiments, the sense strand has a sequence of SEQ ID NO: 109 and the antisense strand has a sequence of SEQ ID NO: 110. In some embodiments, the sense strand has a sequence of SEQ ID NO: 111 and the antisense strand has a sequence of SEQ ID NO: 112. In some embodiments, the sense strand has a sequence of SEQ ID NO: 113 and the antisense strand has a sequence of SEQ ID NO: 114. In some embodiments, the sense strand has a sequence of SEQ ID NO: 115 and the antisense strand has a sequence of SEQ ID NO: 116. In some embodiments, the sense strand has a sequence of SEQ ID NO: 117 and the antisense strand has a sequence of SEQ ID NO: 118. In some embodiments, the sense strand has a sequence of SEQ ID NO: 119 and the antisense strand has a sequence of SEQ ID NO: 120. In some embodiments, the sense strand has a sequence of SEQ ID NO: 121 and the antisense strand has a sequence of SEQ ID NO: 122. In some embodiments, the sense strand has a sequence of SEQ ID NO: 123 and the antisense strand has a sequence of SEQ ID NO: 124. In some embodiments, the sense strand has a sequence of SEQ ID NO: 125 and the antisense strand has a sequence of SEQ ID NO: 126.

In some embodiments, the RNA complex provided herein comprises a chemical modification, wherein the modification facilitates the penetration of a cellular membrane in the absence of a delivery vehicle. In some embodiments, the modification is a 2'-O-methylated nucleoside, a phosphorothioate bond or a cholesterol moiety. In some embodiments, the RNA complex is a modified RNA complex listed in Table 2 or Table 4. In certain embodiments, the RNA complex is not cytotoxic.

The RNA complexes described herein can employ a variety of oligonucleotide chemistries. Examples of oligonucleotide chemistries include, without limitation, peptide nucleic acid (PNA), linked nucleic acid (LNA), phosphorothioate, 2'-O-Me-modified oligonucleotides, and morpholino chemistries, including combinations of any of the foregoing. In general, PNA and LNA chemistries can utilize shorter targeting sequences

because of their relatively high target binding strength relative to 2'-O-Me oligonucleotides. Phosphorothioate and 2'-O-Me-modified chemistries are often combined to generate 2'-O-Me-modified oligonucleotides having a phosphorothioate backbone. See, *e.g.*, PCT Publication Nos. WO/2013/112053 and WO/2009/008725, each of which is hereby
5 incorporated by reference in its entirety.

Peptide nucleic acids (PNAs) are analogs of DNA in which the backbone is structurally homomorphous with a deoxyribose backbone, consisting of N-(2-aminoethyl) glycine units to which pyrimidine or purine bases are attached. PNAs containing natural pyrimidine and purine bases hybridize to complementary oligonucleotides obeying Watson-
10 Crick base-pairing rules, and mimic DNA in terms of base pair recognition. The backbone of PNAs is formed by peptide bonds rather than phosphodiester bonds, making them well-suited for antisense applications (see structure below). The backbone is uncharged, resulting in PNA/DNA or PNA/RNA duplexes that exhibit greater than normal thermal stability. PNAs are not recognized by nucleases or proteases.

15 Despite a radical structural change to the natural structure, PNAs are capable of sequence-specific binding in a helix form to DNA or RNA. Characteristics of PNAs include a high binding affinity to complementary DNA or RNA, a destabilizing effect caused by single-base mismatch, resistance to nucleases and proteases, hybridization with DNA or RNA independent of salt concentration and triplex formation with homopurine DNA.

20 PANAGENE.TM. has developed its proprietary Bts PNA monomers (Bts; benzothiazole-2-sulfonyl group) and proprietary oligomerization process. The PNA oligomerization using Bts PNA monomers is composed of repetitive cycles of deprotection, coupling and capping. PNAs can be produced synthetically using any technique known in the art. See, *e.g.*, U.S. Pat. Nos. 6,969,766, 7,211,668, 7,022,851, 7,125,994, 7,145,006 and 7,179,896. See also
25 U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262 for the preparation of PNAs. Further teaching of PNA compounds can be found in Nielsen *et al.*, *Science*, 254:1497-1500, 1991. Each of the foregoing is incorporated by reference in its entirety.

Interfering nucleic acids may also contain "locked nucleic acid" subunits (LNAs). "LNAs" are a member of a class of modifications called bridged nucleic acid (BNA). BNA
30 is characterized by a covalent linkage that locks the conformation of the ribose ring in a C3'-endo (northern) sugar pucker. For LNA, the bridge is composed of a methylene between the 2'-O and the 4'-C positions. LNA enhances backbone preorganization and base stacking to increase hybridization and thermal stability.

The structures of LNAs can be found, for example, in Wengel, *et al.*, *Chemical Communications* (1998) 455; *Tetrahedron* (1998) 54:3607, and *Accounts of Chem.*

Research (1999) 32:301; Obika, *et al.*, *Tetrahedron Letters* (1997) 38:8735; (1998)

39:5401, and *Bioorganic Medicinal Chemistry* (2008) 16:9230. Compounds provided

5 herein may incorporate one or more LNAs; in some cases, the compounds may be entirely composed of LNAs. Methods for the synthesis of individual LNA nucleoside subunits and their incorporation into oligonucleotides are described, for example, in U.S. Pat. Nos.

7,572,582, 7,569,575, 7,084,125, 7,060,809, 7,053,207, 7,034,133, 6,794,499, and

6,670,461, each of which is incorporated by reference in its entirety. Typical intersubunit

10 linkers include phosphodiester and phosphorothioate moieties; alternatively, non-phosphorous containing linkers may be employed. One embodiment is an LNA-containing compound where each LNA subunit is separated by a DNA subunit. Certain compounds are composed of alternating LNA and DNA subunits where the intersubunit linker is phosphorothioate.

15 In certain embodiments, the RNA complex is linked to a cholesterol moiety. In some embodiments, the cholesterol moiety is attached to the 3' terminus of the sense strand. In some embodiments, the cholesterol moiety is attached to the 3' terminus of the antisense strand. In some embodiments, the cholesterol moiety is attached to the 5' terminus of the sense strand. In some embodiments, the cholesterol moiety is attached to the 5' terminus of

20 the antisense strand.

In some embodiments, the RNA complex comprises a 2'-O-methylated nucleoside. 2'-O-methylated nucleosides carry a methyl group at the 2'-OH residue of the ribose molecule. 2'-O-Me-RNAs show the same (or similar) behavior as RNA, but are protected against nuclease degradation. 2'-O-Me-RNAs can also be combined with phosphothioate

25 oligonucleotides (PTOs) for further stabilization. 2'-O-Me-RNAs (phosphodiester or phosphothioate) can be synthesized according to routine techniques in the art (see, *e.g.*, Yoo *et al.*, *Nucleic Acids Res.* 32:2008-16, 2004, which is hereby incorporated by reference).

In some embodiments, the 2'-O-methyl nucleoside is positioned at the 3' terminus of the sense strand. In some embodiments, 3' terminal region of the sense strand comprises a

30 plurality of 2'-O-methylated nucleosides (*e.g.*, 2, 3, 4, 5 or 6 2'-O-methylated nucleosides within 6 nucleosides of the 3' terminus). In some embodiments, the 2'-O-methyl nucleoside is positioned at the 3' terminus of the antisense strand. In some embodiments, 3' terminal region of the antisense strand comprises a plurality of 2'-O-methylated nucleosides (*e.g.*, 2,

3, 4, 5 or 6 2'-O-methylated nucleosides within 6 nucleosides of the 3' terminus). In some embodiments, both the 3' terminal region of the sense strand and the 3' terminal region of the antisense strand comprise a plurality of 2'-O-methylated nucleosides. In some embodiments, the sense strand comprises 2'-O-methylated nucleosides that alternate with unmodified nucleosides. In some embodiments, the sense strand comprises a contiguous sequence of 2, 3, 4, 5, 6, 7 or 8 2'-O-methylated nucleosides that alternate with unmodified nucleosides. In some embodiments, the anti-sense strand comprises 2'-O-methylated nucleosides that alternate with unmodified nucleosides. In some embodiments, the anti-sense strand comprises a contiguous sequence of 2, 3, 4, 5, 6, 7 or 8 2'-O-methylated nucleosides that alternate with unmodified nucleosides.

In some embodiments, the RNA complex comprises a phosphorothioate bond. "Phosphorothioates" (or S-oligos) are a variant of normal DNA in which one of the nonbridging oxygens is replaced by a sulfur. The sulfurization of the internucleotide bond reduces the action of endo- and exonucleases including 5' to 3' and 3' to 5' DNA POL I exonuclease, nucleases S1 and P1, RNases, serum nucleases and snake venom phosphodiesterase. Phosphorothioates are made by two principal routes: by the action of a solution of elemental sulfur in carbon disulfide on a hydrogen phosphonate, or by the method of sulfurizing phosphite triesters with either tetraethylthiuram disulfide (TETD) or 3H-1,2-benzodithiol-3-one 1,1-dioxide (BDTD) (see, *e.g.*, Iyer *et al.*, *J. Org. Chem.* 55, 4693-4699, 1990). The latter methods avoid the problem of elemental sulfur's insolubility in most organic solvents and the toxicity of carbon disulfide. The TETD and BDTD methods also yield higher purity phosphorothioates.

In some embodiments, at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the bonds between the ribonucleotides in the sense strand of the RNA complex are phosphorothioate bonds. In some embodiments, all of the bonds between the ribonucleotides in the sense strand of the RNA complex are phosphorothioate bonds.

In some embodiments, at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the bonds between the ribonucleotides in the antisense strand of the RNA complex are phosphorothioate bonds. In some embodiments, all of the bonds between the ribonucleotides in the antisense strand of the RNA complex are phosphorothioate bonds.

The RNA complexes described herein may be contacted with a cell or administered to an organism (*e.g.*, a human). Alternatively, constructs and/or vectors encoding the RNA complexes may be contacted with or introduced into a cell or organism. In certain embodiments, a viral, retroviral or lentiviral vector is used.

- 5 The RNA complexes described herein can be prepared by any appropriate method known in the art. For example, in some embodiments, the RNA complexes described herein are prepared by chemical synthesis or *in vitro* transcription.

Pharmaceutical Compositions

- 10 In certain aspects, provided herein is a pharmaceutical composition comprising an RNA complex provided herein and a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition is formulated for topical delivery. In some embodiments, the pharmaceutical composition is a cream or a lotion. In some embodiments, the pharmaceutical composition further comprises a second skin lightening agent (*e.g.*, hydroquinone, arbutin, tretinoin, kojic acid, azelaic acid or tranexamic acid). In 15 certain embodiments, the pharmaceutical composition does not comprise a transfection vehicle. In some embodiments, the pharmaceutical composition comprises a delivery vehicle (*e.g.*, liposomes, cationic polymers, cell penetrating peptides (CPPs), protein transduction domains (PTDs), antibodies and/or aptamers). In some embodiments, the composition includes a combination of multiple (*e.g.*, two or more) of the RNA complexes 20 described herein.

As described in detail below, the pharmaceutical compositions disclosed herein may be specially formulated for administration in solid or liquid form, including those adapted for topical administration (*e.g.*, as a cream or lotion).

- 25 Methods of preparing these formulations or compositions include the step of bringing into association an RNA complex described herein with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association an agent described herein with liquid carriers.

- 30 The pharmaceutical compositions described herein can be provided in any cosmetically and/or dermatologically suitable form, for example, an emulsion, a cream, a mousse, a gel, a foam, a lotion, a mask, an ointment, a pomade, a solution, a serum, a spray, a stick, a patch, or a towelette. For example, pharmaceutical compositions for topical administration can be more or less fluid and have the appearance of a white or colored cream, of an ointment, of a milk, of a lotion, of a serum, of a paste, of a mousse or of a gel.

It can, where appropriate, be applied to the skin in the form of an aerosol. It can also be present in solid form and, for example, be in the form of a stick. It can be used as a care product and/or as a skin makeup product.

In some embodiments, the pharmaceutical compositions described herein can, in addition to the RNA complex, contain at least one compound selected from: hydroquinone, 5 arbutin, tretinoin, azelaic acid, tranexamic acid, α -hydroxyacids; salicylic acid and its derivatives such as n-octanoyl-5-salicylic acid; HEPES; procysteine; O-octanoyl-6-D-maltose; the disodium salt of methylglycinediacetic acid; ceramides; steroids such as diosgenin and derivatives of DHEA; kojic acid; N-ethyloxycarbonyl-4-paraaminophenol; 10 ascorbic acid and its derivatives; bilberry extracts; retinoids and, in particular, retinol and its esters; polypeptides and their acylated derivatives; phytohormones; extracts of the yeast *Saccharomyces cerevisiae*; algal extracts; extracts of *Vitreoscilla filiformis*; extracts of soybean, lupin, corn and/or pea; alverine and its salts, in particular alverine citrate; resveratrol; carotenoids and, in particular, lycopene; tocopherol and its esters; coenzyme 15 Q10 or ubiquinone; xanthines and, in particular, caffeine and the natural extracts containing it; extracts of butcher's-broom and horse-chestnut; and their mixtures.

In some embodiments, the pharmaceutical compositions described herein can contain at least one UVA and/or UVB filter. The sunscreen filters can be selected from organic filters and inorganic filters and combinations thereof.

20 Examples of organic filters that block transmission of UV-A and/or the UV-B include: derivatives of paraminobenzoic acid (*e.g.*, PABA, ethyl PABA, ethyldihydroxypropyl PABA, ethylhexyldimethyl PABA, glyceryl PABA, PEG-25 PABA), salicylic derivatives (*e.g.*, homosalate, ethylhexyl salicylate, dipropyleneglycol salicylate, TEA salicylate) derivatives of dibenzoylmethane (*e.g.*, butylmethoxydibenzoylmethane, 25 isopropylidibenzoylmethane), cinnamic derivatives (*e.g.*, ethylhexyl methoxycinnamate, isopropylmethoxycinnamate, isoamylmethoxycinnamate, cinoxate, DEA methoxycinnamate, diisopropyl methylcinnamate, glyceryl ethylhexanoate dimethoxycinnamate), derivatives of β,β' -diphenylacrylate (*e.g.*, octocrylene, etocrylene), derivatives of benzophenone (*e.g.*, benzophenone-1, benzophenone-2, benzophenone-3 or 30 oxybenzone, benzophenone-4, benzophenone-5, benzophenone-6, benzophenone-8, benzophenone-9, and benzophenone-12), derivatives of benzylidene camphor (*e.g.*, 3-benzylidene camphor, 4-methylbenzylidene camphor, benzylidene camphor sulfonic acid, camphor benzalkonium methosulfate, terephthalylidene dicamphor sulfonic acid and

polyacrylamidomethyl benzylidene camphor), derivatives of phenyl benzimidazole (*e.g.*, phenylbenzimidazole sulfonic acid, and benzimidazilate), derivatives of triazine (*e.g.*, anisotriazine, ethylhexyl triazone, and diethylhexyl-butamidotriazone), derivatives of phenyl benzotriazole (*e.g.*, drometrizole trisiloxane), anthranilic derivatives (menthyl
 5 anthranilate), imidazoline derivatives (*e.g.*, ethylhexyldimethoxy-benzylidenedioxiimidazoline propionate), derivatives of benzalmalonate (polyorganosiloxane) and combinations thereof.

Examples of inorganic filters that block transmission of UV-A and/or the UV-B include: or uncoated metallic oxide nanopigments (mean size of the primary particles: in
 10 general, from 5 nm to 100 nm, preferably from 10 nm to 50 nm), such as nanopigments of titanium oxide (amorphous or crystallized in rutile and/or anatase form), of iron oxide, of zinc oxide, of zirconium oxide or of cerium oxide. Coating agents are, in addition, alumina and/or aluminum stearate.

In certain embodiments, the pharmaceutical compositions described herein also
 15 contain other cosmetic and dermatological ingredients, such as hydrophilic or lipophilic gelatinizing agents, preservatives, antioxidants, solvents, surfactants, thickeners, perfumes, fillers, pigments, odor absorbers and coloring substances.

In certain embodiments, the pharmaceutical compositions described herein also contain oils. Examples of oils that can be included in the pharmaceutical composition
 20 described herein include: hydrocarbonaceous oils of animal origin (*e.g.*, perhydrosqualene), hydrocarbonaceous oils of vegetable origin (*e.g.*, liquid fatty acid triglycerides which comprise from 4 to 10 carbon atoms and the liquid fraction of karite butter), synthetic esters and ethers of fatty acids (*e.g.*, the oils of the formulae R^1COOR^2 and R^1OR^2 in which R^1 represents the residue of a fatty acid comprising from 8 to 29 carbon atoms and R^2
 25 represents a branched or unbranched hydrocarbon chain which contains from 3 to 30 carbon atoms, such as Purcellin's oil, isononyl isononanoate, isopropyl myristate, ethyl-2-hexyl palmitate, octyl-2-dodecyl stearate, octyl-2-dodecyl erucate, and isostearyl isostearate; hydroxylated esters such as isostearyl lactate, octylhydroxystearate, octyldodecyl hydroxystearate, diisostearylmalate, triisocetyl citrate, and heptanoates, octanoates and
 30 decanoates of fatty alcohols; polyol esters, such as propylene glycol dioctanoate, neopentylglycol diheptanoate and diethyleneglycol diisononanoate; and pentaerythritol esters, such as pentaerythrityl tetraisostearate), linear or branched hydrocarbons of mineral or synthetic origin (*e.g.*, volatile or nonvolatile paraffin oils and their derivatives,

petrolatum, polydecenes, and hydrogenated polyisobutene such as parleam oil), fatty alcohols having from 8 to 26 carbon atoms (*e.g.*, cetyl alcohol and stearyl alcohol and their mixture octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2-undecylpentadecanol, oleic alcohol or linoleic alcohol), partially hydrocarbonaceous and/or siliconaceous fluorinated oils, silicone oils (*e.g.*, volatile or nonvolatile polymethylsiloxanes (PDMS) which have a linear or cyclic siliconaceous chain and which are liquid or pasty at ambient temperature, in particular cyclopoly-dimethylsiloxanes (cyclomethicones) such as cyclohexasiloxane; polydimethylsiloxanes which comprise alkyl, alkoxy or phenyl groups which are pendent or at the end of the siliconaceous chain, with the groups having from 2 to 24 carbon atoms; phenylated silicones such as phenyltrimethicones, phenyldimethicones, phenyl-trimethylsiloxydiphenylsiloxanes, diphenyldimethicones, diphenylmethyldiphenyltrisiloxanes, 2-phenylethyltrimethylsiloxysilicates and polymethylphenylsiloxanes), and combinations thereof.

Examples of emulsifiers and coemulsifiers which can be included in the pharmaceutical compositions described herein include O/W emulsifiers, such as esters of fatty acid and polyethylene glycol, in particular PEG-100 stearate, and esters of fatty acid and glycerol, such as glyceryl stearate, as well as W/O emulsifiers such as the oxyethylenated poly(methylcetyl)(dimethyl)-methylsiloxane or the mixture of ethylene glycol acetyl stearate and glyceryl tristearate.

Hydrophilic gelatinizing agents that can be included in the pharmaceutical compositions described herein include carboxyvinyl polymers (carbomer), acrylic polymers such as acrylate/alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, while lipophilic gelatinizing agents which may be mentioned are modified clays such as bentonites, metallic salts of fatty acids, hydrophobic silica and polyethylenes.

Examples of fillers that may be included in the pharmaceutical compositions described herein include pigments, silica powder, talc, starch which is crosslinked with octenylsuccinic anhydride, polyamide particles, polyethylene powders, microspheres based on acrylic copolymers, expanded powders such as hollow microspheres, silicone resin microbeads and combinations thereof.

In certain embodiments, the pharmaceutical compositions described herein are formulated for transdermal modes of delivery, such as patches and the like, with or without a suitable skin penetration enhancer. Accordingly, a transdermal means of delivering a

composition or formulation (often with a skin penetration enhancer composition) to the skin is that of the transdermal patch or a similar device as known and described in the art.

Examples of such devices are disclosed in U.S. Pat. Nos. 5,146,846, 5,223,262, 4,820,724, 4,379,454 and 4,956,171, each of which is hereby incorporated by reference. In some
5 embodiments, the composition described herein is delivered by a microneedle patch. Exemplary microneedle patches are described in U.S. Pat. Nos. 5,697,901, 6,503,231, 6,611,707, 6,660,987, 8,162,901, 8,696,637 and 8,784,363, each of which is hereby incorporated by reference.

10 Therapeutic Methods

 In certain aspects, provided herein is a method of inhibiting tyrosinase expression by a cell (*e.g.*, a melanocyte) comprising contacting the cell with an RNA complex provided herein. In some embodiments, the RNA complex is a modified RNA complex and the cell is contacted with the RNA complex in the absence of a transfection vehicle. In
15 some embodiments, the cell is contacted with the RNA complex in the presence of a delivery vehicle (*e.g.*, a liposome, cationic polymer, cell penetrating peptide (CPPs), protein transduction domain (PTDs), antibody and/or aptamer). In some embodiments, the cell is present in the skin of a human subject. In some embodiments, the subject has a skin pigmentation disorder associated with excessive melanin production (*e.g.*, melasma or age
20 spots). In some embodiments, the subject is female. In some embodiments, the subject is pregnant or is taking oral or patch contraceptives or is undergoing hormone replacement therapy.

 In certain aspects, provided herein is a method of inhibiting melanin production by a cell (*e.g.*, a melanocyte) comprising contacting the cell with an RNA complex provided
25 herein. In some embodiments, the RNA complex is a modified RNA complex and the cell is contacted with the RNA complex in the absence of a transfection vehicle. In some embodiments, the cell is contacted with the RNA complex in the presence of a delivery vehicle (*e.g.*, a liposome, cationic polymer, cell penetrating peptide (CPPs), protein transduction domain (PTDs), antibody and/or aptamer). In some embodiments, the cell is
30 present in the skin of a human subject. In some embodiments, the subject has a skin pigmentation disorder associated with excessive melanin production (*e.g.*, melasma or age spots). In some embodiments, the subject is female. In some embodiments, the subject is

pregnant or is taking oral or patch contraceptives or is undergoing hormone replacement therapy.

In certain aspects, provided herein is a method of inhibiting melanin production in the skin of a human subject comprising administering to the subject an RNA complex or pharmaceutical composition provided herein. In some embodiments, the subject has a skin pigmentation disorder associated with excessive melanin production (*e.g.*, melasma or age spots). In some embodiments, the subject is female. In some embodiments, the subject is pregnant or is taking oral or patch contraceptives or is undergoing hormone replacement therapy. In certain embodiments, the RNA complex or pharmaceutical composition is administered topically to the skin of the subject. In some embodiments, the RNA complex or pharmaceutical composition is self-administered by the subject. In some embodiments, the method further comprises administering to the subject a second skin lightening agent (*e.g.*, hydroquinone, arbutin, tretinoin, kojic acid, azelaic acid or tranexamic acid).

In certain aspects, provided herein is a method of treating a human subject for a skin pigmentation disorder associated with excessive melanin production (*e.g.*, melasma or age spots) comprising administering to the subject an RNA complex or pharmaceutical composition provided herein. In some embodiments, the subject is female. In some embodiments, the subject is pregnant or is taking oral or patch contraceptives or is undergoing hormone replacement therapy. In certain embodiments, the RNA complex or pharmaceutical composition is administered topically to the skin of the subject. In some embodiments, the RNA complex or pharmaceutical composition self-administered by the subject. In some embodiments, the method further comprises administering to the subject a second skin lightening agent (*e.g.*, hydroquinone, arbutin, tretinoin, kojic acid, azelaic acid or tranexamic acid).

In the present methods, an RNA complex described herein can be administered to the subject, for example, as nucleic acid without delivery vehicle (*e.g.*, for cp-asiRNAs and cp-lasiRNAs), in combination with a delivery reagent, and/or as a nucleic acid comprising sequences that express the RNA complex described herein. In some embodiments, any nucleic acid delivery method known in the art can be used in the methods described herein. Suitable delivery reagents include, but are not limited to, *e.g.*, the Mirus Transit TKO lipophilic reagent; lipofectin; lipofectamine; cellfectin; polycations (*e.g.*, polylysine), atelocollagen, nanoplexes and liposomes. The use of atelocollagen as a delivery vehicle for nucleic acid molecules is described in Minakuchi *et al. Nucleic Acids Res.*, 32(13):e109

(2004); Hanai *et al. Ann NY Acad Sci.*, 1082:9-17 (2006); and Kawata *et al. Mol Cancer Ther.*, 7(9):2904-12 (2008); each of which is incorporated herein in their entirety.

Exemplary interfering nucleic acid delivery systems are provided in U.S. Patent Nos. 8,283,461, 8,313,772, 8,501,930, 8,426,554, 8,268,798 and 8,324,366, each of which is
5 hereby incorporated by reference in its entirety.

In some embodiments of the methods described herein, liposomes are used to deliver an RNA complex described herein to a subject. Liposomes suitable for use in the methods described herein can be formed from standard vesicle-forming lipids, which generally include neutral or negatively charged phospholipids and a sterol, such as
10 cholesterol. The selection of lipids is generally guided by consideration of factors such as the desired liposome size and half-life of the liposomes in the blood stream. A variety of methods are known for preparing liposomes, for example, as described in Szoka *et al.* (1980), *Ann. Rev. Biophys. Bioeng.* 9:467; and U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, the entire disclosures of which are herein incorporated by
15 reference.

The liposomes for use in the present methods can also be modified so as to avoid clearance by the mononuclear macrophage system ("MMS") and reticuloendothelial system ("RES"). Such modified liposomes have opsonization-inhibition moieties on the surface or incorporated into the liposome structure.

20 Opsonization-inhibiting moieties for use in preparing the liposomes described herein are typically large hydrophilic polymers that are bound to the liposome membrane. As used herein, an opsonization inhibiting moiety is "bound" to a liposome membrane when it is chemically or physically attached to the membrane, *e.g.*, by the intercalation of a lipid-soluble anchor into the membrane itself, or by binding directly to active groups of
25 membrane lipids. These opsonization-inhibiting hydrophilic polymers form a protective surface layer that significantly decreases the uptake of the liposomes by the MMS and RES; *e.g.*, as described in U.S. Pat. No. 4,920,016, the entire disclosure of which is herein incorporated by reference.

In some embodiments, opsonization inhibiting moieties suitable for modifying
30 liposomes are water-soluble polymers with a number-average molecular weight from about 500 to about 40,000 daltons, or from about 2,000 to about 20,000 daltons. Such polymers include polyethylene glycol (PEG) or polypropylene glycol (PPG) derivatives; *e.g.*, methoxy PEG or PPG, and PEG or PPG stearate; synthetic polymers such as

polyacrylamide or poly N-vinyl pyrrolidone; linear, branched, or dendrimeric polyamidoamines; polyacrylic acids; polyalcohols, *e.g.*, polyvinylalcohol and polyxylitol to which carboxylic or amino groups are chemically linked, as well as gangliosides, such as ganglioside GM1. Copolymers of PEG, methoxy PEG, or methoxy PPG, or derivatives thereof, are also suitable. In addition, the opsonization inhibiting polymer can be a block copolymer of PEG and either a polyamino acid, polysaccharide, polyamidoamine, polyethyleneamine, or polynucleotide. The opsonization inhibiting polymers can also be natural polysaccharides containing amino acids or carboxylic acids, *e.g.*, galacturonic acid, glucuronic acid, mannuronic acid, hyaluronic acid, pectic acid, neuraminic acid, alginic acid, carrageenan; aminated polysaccharides or oligosaccharides (linear or branched); or carboxylated polysaccharides or oligosaccharides, *e.g.*, reacted with derivatives of carbonic acids with resultant linking of carboxylic groups. In some embodiments, the opsonization-inhibiting moiety is a PEG, PPG, or derivatives thereof. Liposomes modified with PEG or PEG-derivatives are sometimes called "PEGylated liposomes."

The pharmaceutical compositions disclosed herein may be delivered by any suitable route of administration, including topically, orally and parenterally. In certain embodiments the pharmaceutical compositions are delivered generally (*e.g.*, via oral or parenteral administration). In certain other embodiments the pharmaceutical compositions are delivered locally through direct administration to the skin.

Actual dosage levels of the RNA complexes in the pharmaceutical compositions may be varied so as to obtain an amount of RNA complex that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

The selected dosage level will depend upon a variety of factors including the activity of the particular agent employed, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

A physician having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could prescribe and/or administer doses of the agents employed in the

pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. Similarly, an individual user could apply increasing amounts of the composition until the desired level of whitening is achieved.

- 5 In general, a suitable daily dose of an RNA complex described herein will be that amount of the RNA complex which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.

EXEMPLIFICATION

Example 1: Screening for tyrosinase-specific asymmetric small interfering RNAs

- 10 To identify asymmetric small interfering RNAs (asiRNAs) that inhibit tyrosinase with high efficiency, 62 asiRNAs were synthesized and screened. The nucleic acid sequences of the screened asiRNAs are provided in Table 1.

Table 1: Nucleic acid sequences for exemplary tyrosinase-targeting asiRNA.

SEQ ID NO.:	SEQUENCE
1	asiTYR(1)S : CAGGGCUUGUGAGCUU
2	asiTYR(1)AS : AAGCUCACAAGCCCUGCCAGC
3	asiTYR(2)S : AUAGAGUAGGGCCAAA
4	asiTYR(2)AS : UUUGGCCCACUCUAUUGCCU
5	asiTYR(3)S : GAAAUCCAGAAGCUGA
6	asiTYR(3)AS : UCAGCUUCUGGAUUUCUUGUU
7	asiTYR(4)S : GCUGACAGGAGAUGAA
8	asiTYR(4)AS : UUCAUCUCCUGUCAGCUUCUG
9	asiTYR(5)S : AACAAAGAAUCCAGAA
10	asiTYR(5)AS : UUCUGGAUUUCUUGUCCCCAC
11	asiTYR(6)S : GAUUGGAGGAGUACAA
12	asiTYR(6)AS : UUGUACUCCUCCAAUCGGCUA
13	asiTYR(7)S : ACAAGCGAGUCGGAUC
14	asiTYR(7)AS : GAUCCGACUCGCUUGUUCCAA
15	asiTYR(8)S : GCCGAUUGGAGGAGUA
16	asiTYR(8)AS : UACUCCUCCAAUCGGCUACUA
17	asiTYR(9)S : UGAAGCACCAGCUUUU
18	asiTYR(9)AS : AAAAGCUGGUGCUUCAUGGGC
19	asiTYR(10)S : AAUGAAAAAUGGAUCA
20	asiTYR(10)AS : UGAUCCAUUUUUCAUUUGGCC
21	asiTYR(11)S : ACAAGAAAUCCAGAAG
22	asiTYR(11)AS : CUUCUGGAUUUCUUGUCCCCA

23	asiTYR(12)S : CCGAUUGGAGGAGUAC
24	asiTYR(12)AS : GUACUCCUCCAAUCGGCUACA
25	asiTYR(13)S : CAGCUGAUGUAGAAUU
26	asiTYR(13)AS : AAUUCUACAUCAGCUGAAGAG
27	asiTYR(14)S : CUGGCGGGAUGCAGAA
28	asiTYR(14)AS : UUCUGCAUCCCGCCAGUCCCA
29	asiTYR(15)S : AGGAGUACAACAGCCA
30	asiTYR(15)AS : UGGCUGUUGUACUCCUCCAAU
31	asiTYR(16)S : GCUAUGACUAUAGCUA
32	asiTYR(16)AS : UAGCUAUAGUCAUAGCCCAGA
33	asiTYR(17)S : CCCAUGUUUAACGACA
34	asiTYR(17)AS : UGUCGUUAAACAUGGGUGUUG
35	asiTYR(18)S : UAGACUCUUCUUGUUG
36	asiTYR(18)AS : CAACAAGAAGAGUCUAUGCCA
37	asiTYR(19)S : CUGUGGAGUUUCCAGA
38	asiTYR(19)AS : UCUGGAAACUCCACAGCAGGC
39	asiTYR(20)S : CAGGCAGAGGUUCCUG
40	asiTYR(20)AS : CAGGAACCUCUGCCUGAAAGC
41	asiTYR(21)S : GGACCUGCCAGUGCUC
42	asiTYR(21)AS : GAGCACUGGCAGGUCCUAUUA
43	asiTYR(22)S : UACUCAGCCCAGCAUC
44	asiTYR(22)AS : GAUGCUGGGCUGAGUAAGUUA
45	asiTYR(23) S : UCAGUCUUUAUGCAAU
46	asiTYR(23) AS : AUUGCAUAAAGACUGAUGGCU
47	asiTYR(24) S : ACAAGAUUCAGACCCA
48	asiTYR(24) AS : UGGGUCUGAAUCUUGUAGAU
49	asiTYR(25) S : CAAGCGAGUCGGAUCU
50	asiTYR(25) AS : AGAUCCGACUCGCUUGUCCA
51	asiTYR(26) S : UAAAAGGCUUAGGCAA
52	asiTYR(26) AS : UUGCCUAAGCCUUUUAUAAAU
53	asiTYR(27) S : CUAUAUGAAUGGAACA
54	asiTYR(27) AS : UGUUCCAUAUCAUAUAGAUGUG
55	asiTYR(28) S : AAGAUCUGGGCUAUGA
56	asiTYR(28) AS : UCAUAGCCCAGAUUUUGGAU
57	asiTYR(29) S : GUCCAAUGCACCACUU
58	asiTYR(29) AS : AAGUGGUGCAUUGGACAGAAG
59	asiTYR(30) S : UCACAGGGGUGGAUGA
60	asiTYR(30) AS : UCAUCCACCCCUGUGAAGGGA
61	asiTYR(31) S : GGCCUCCGUCUUUUA
62	asiTYR(31) AS : UAAAAGACGGAAGGCCACGAC

63	asiTYR(32) S : CUGCAAGUUUGGCUUU
64	asiTYR(32) AS : AAAGCCAAACUUGCAGUUUCC
65	asiTYR(33) S : CAGAGAAGGACAAAUAU
66	asiTYR(33) AS : AAUUUGUCCUUCUCUGGGGCA
67	asiTYR(34) S : GCAUACCAUCAGCUCA
68	asiTYR(34) AS : UGAGCUGAUGGUAUGCUUUGC
69	asiTYR(35) S : UUGGGGGAUCUGAAAU
70	asiTYR(35) AS : AUUUCAGAUCCCCCAAGCAGU
71	asiTYR(36) S : UCAGCACCCCACAAAUAU
72	asiTYR(36) AS : AUUUGUGGGGUGCUGACCUCC
73	asiTYR(37) S : GCCCGAGGGACCUUUA
74	asiTYR(37) AS : UAAAGGUCCCUCGGGCGUUC
75	asiTYR(38) S : CCAUGUUUAACGACAU
76	asiTYR(38) AS : AUGUCGUAAACAUGGGUGUU
77	asiTYR(39) S : UGACAGGAGAUGAAAA
78	asiTYR(39) AS : UUUUCAUCUCCUGUCAGCUUC
79	asiTYR(40) S : CAACUUCAUGGGAUUC
80	asiTYR(40) AS : GAAUCCCAUGAAGUUGCCAGA
81	asiTYR(41) S : GUUCCUGUCAGAAUAU
82	asiTYR(41) AS : AUAUUCUGACAGGAACCUCUG
83	asiTYR(42) S : CCUAUGGCCAAAUGAA
84	asiTYR(42) AS : UUCAUUUGGCCAUAGGUCCCU
85	asiTYR(43) S : UUCCUGUCAGAAUAUC
86	asiTYR(43) AS : GAUAUUCUGACAGGAACCUCU
87	asiTYR(44) S : AGGUUCCUGUCAGAAU
88	asiTYR(44) AS : AUUCUGACAGGAACCUCUGCC
89	asiTYR(45) S : GGCAACUUCAUGGGAU
90	asiTYR(45) AS : AUCCCAUGAAGUUGCCAGAGC
91	asiTYR(46) S : AACUUCAUGGGAUUA
92	asiTYR(46) AS : UGAAUCCCAUGAAGUUGCCAG
93	asiTYR(47) S : ACCUAUGGCCAAAUGA
94	asiTYR(47) AS : UCAUUUGGCCAUAGGUCCCUA
95	asiTYR(48) S : UAUGGCCAAAUGAAAA
96	asiTYR(48) AS : UUUUCAUUUGGCCAUAGGUCC
97	asiTYR(49) S : CUGACAGGAGAUGAAA
98	asiTYR(49) AS : UUUCAUCUCCUGUCAGCUUCU
99	asiTYR(50) S : AGCUGACAGGAGAUGA
100	asiTYR(50) AS : UCAUCUCCUGUCAGCUUCUGG
101	asiTYR(51) S : ACCCAUGUUUAACGAC
102	asiTYR(51) AS : GUCGUUAAACAUGGGUGUUGA

103	asiTYR(52) S : AACACCCAUGUUUAAAC
104	asiTYR(52) AS : GUUAAACAUGGGUGUUGAUCC
105	asiTYR(53) S : CAGUCUUUAUGCAAUG
106	asiTYR(53) AS : CAUUGCAUAAAGACUGAUGGC
107	asiTYR(54) S : AUCAGUCUUUAUGCAA
108	asiTYR(54) AS : UUGCAUAAAGACUGAUGGCUG
109	asiTYR(55) S : CUUGGUGAGAAGAAAC
110	asiTYR(55) AS : GUUUCUUCACCAAGAGUCG
111	asiTYR(56) S : CUGCCAACGAUCCUAU
112	asiTYR(56) AS : AUAGGAUCGUUGGCAGAUCCC
113	asiTYR(57) S : UCCUACAUGGUUCCUU
114	asiTYR(57) AS : AAGGAACCAUGUAGGAUUCCC
115	asiTYR(58) S : CUUUGUCUGGAUGCAU
116	asiTYR(58) AS : AUGCAUCCAGACAAAGAGGUC
117	asiTYR(59) S : ACAUUUGCACAGAUGA
118	asiTYR(59) AS : UCAUCUGUGCAA AUGUCACAC
119	asiTYR(60) S : GCGGAUGCCUCUCAA
120	asiTYR(60) AS : UUUGAGAGGCAUCCGCUAUCC
121	asiTYR(61) S : AACCGGGAUCCUACA
122	asiTYR(61) AS : UGUAGGAUUCGCGUUAUGUC
123	asiTYR(62) S : GGACAUAACCGGGAU
124	asiTYR(62) AS : AUUCCCGGUUAUGUCCAAUGG

The asiRNAs listed in Table 1 were incubated at 95 °C for 2 minutes and at 37 °C for 1 hour in 1x siRNA duplex buffer (STpharm). Proper strand annealing was confirmed via gel electrophoresis. For the screen, 1.6×10^4 A375 cells (ATCC) that had been cultured in Dulbecco's modified Eagle's medium (Gibco) containing 10% fetal bovine serum (Gibco) and 100 µg/ml penicillin / streptomycin in a 100 mm cell culture dish were seeded in 24-well plates. The A375 cells were transfected with 0.3 nM of the asiRNAs using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions.

The tyrosinase mRNA levels in the transfected cells were measured 24 hours after transfection using real-time RTPCR. Specifically, total RNA were extracted using Isol-RNA lysis reagent (5PRIME), and then 500 ng of the extracted RNA was used for cDNA synthesis using the High-capacity cDNA reverse transcription kit (Applied Biosystems), according to the manufacturer's instructions. The synthesized cDNA was diluted and then quantitative real-time PCR was performed using the StepOne real-time PCR system (Applied Biosystems) according to manufacturer's instructions. Amplification of the

tyrosinase gene was detected using a power SYBR green PCR master Mix (Applied Biosystems). GAPDH was amplified as an internal control. The following primer sequences were used:

- 5 *Human GAPDH*-forward 5'-GAG TCA ACG GAT TTG GTC GT-3' (SEQ ID NO:125)
Human GAPDH-reverse 5'-GAC AAG CTT CCC GTT CTC AG-3' (SEQ ID NO: 126)
Human Tyrosinase-forward : 5'-GGA TCT GGT CAT GGC TCC TT-3' (SEQ ID NO: 127)
Human Tyrosinase-reverse : 5'-GTC AGG CTT TTT GGC CCT AC-3' (SEQ ID NO: 128)

- 10 The level of tyrosinase inhibition by each of the 62 asiRNAs is provided in Figure 1. Six of the asiRNA sequences, asiTYR(4), asiTYR(9), asiTYR(10), asiTYR(17), asiTYR(44) and asiTYR(45), were selected for use in follow-up studies.

Example 2: Chemical modification of asiRNAs for self-delivery

- Chemical modifications were applied to the six asiRNAs selected in Example 1 and
 15 the cellular delivery of the modified asiRNAs was tested in the absence of other delivery vehicle. As described below, certain of the modifications improved endocytosis and stability of the asiRNAs. Such cell penetrating asiRNAs (cp-asiRNAs) are able to be delivered into the cell in the absence of a delivery vehicle.

- Thirty-eight potential cp-asiRNAs (Table 2) were screened for tyrosinase mRNA
 20 inhibition in MNT-1 cells. Each potential cp-asiRNA was incubated with MNT-1 cells, a human melanoma cell line, at 1 μ M without a delivery vehicle and tyrosinase mRNA levels were measured by Real-Time PCR.

- 25 **Table 2. Modified asiRNA sequences tested for self-delivery and tyrosinase inhibition. m = 2'-O-Methyl RNA. * = phosphorothioate bond.**

asiTYR(4)-1 S : GCUGACAGGAGAUG*A*A*cholesterol
asiTYR(4)-1 AS : UUCAUCUCCUGUCAGCU*U*C*U*G
asiTYR(4)-2 S : GCUGACAGGAGAUG*A*A*cholesterol
asiTYR(4)-2 AS : UUCAUCUCCUGUCAGCU*U*mC*mU*mG
asiTYR(4)-3 S : GCUGACAGGAGAUG*A*A*cholesterol
asiTYR(4)-3 AS : UUCAUCUCCUGUCAGCmU*mU*mC*mU*mG
asiTYR(4)-4 S : mGCmUGmACmAGmGAmGAmUG*mA*A*cholesterol
asiTYR(4)-4 AS : UUCAUCUCCUGUCAGCU*U*C*U*G
asiTYR(4)-5 S : mGCmUGmACmAGmGAmGAmUG*mA*A*cholesterol
asiTYR(4)-5 AS : UUCAUCUCCUGUCAGCU*U*mC*mU*mG
asiTYR(4)-6 S : mGCmUGmACmAGmGAmGAmUG*mA*A*cholesterol
asiTYR(4)-6 AS : UUCAUCUCCUGUCAGCmU*mU*mC*mU*mG

asiTYR(9)-1 S : UGAAGCACCAGCUU*U*U*cholesterol
asiTYR(9)-1 AS : AAAAGCUGGUGCUUCAU*G*G*G*C
asiTYR(9)-3 S : UGAAGCACCAGCUU*U*U*cholesterol
asiTYR(9)-3 AS : AAAAGCUGGUGCUUCAmU*mG*mG*mG*mC
asiTYR(9)-4 S : mUGmAAmGCmACmCAmGCmUU*mU*U*cholesterol
asiTYR(9)-4 AS : AAAAGCUGGUGCUUCAU*G*G*G*C
asiTYR(9)-6 S : mUGmAAmGCmACmCAmGCmUU*mU*U*cholesterol
asiTYR(9)-6 AS : AAAAGCUGGUGCUUCAmU*mG*mG*mG*mC
asiTYR(10)-1 S : AAUGAAAAAUGGAU*C*A*cholesterol
asiTYR(10)-1 AS : UGAUCCAUUUUUCAUUU*G*G*C*C
asiTYR(10)-3 S : AAUGAAAAAUGGAU*C*A*cholesterol
asiTYR(10)-3 AS : UGAUCCAUUUUUCAUUmU*mG*mG*mC*mC
asiTYR(10)-4 S : mAAmUGmAAmAAmAUmGGmAU*mC*A*cholesterol
asiTYR(10)-4 AS : UGAUCCAUUUUUCAUUU*G*G*C*C
asiTYR(10)-6 S : mAAmUGmAAmAAmAUmGGmAU*mC*A*cholesterol
asiTYR(10)-6 AS : UGAUCCAUUUUUCAUUmU*mG*mG*mC*mC
asiTYR(17)-1 S : CCCAUGUUUAACGA*C*A*cholesterol
asiTYR(17)-1 AS : UGUCGUUAAACAUGGGU*G*U*U*G
asiTYR(17)-2 S : CCCAUGUUUAACGA*C*A*cholesterol
asiTYR(17)-2 AS : UGUCGUUAAACAUGGGU*G*mU*mU*mG
asiTYR(17)-3 S : CCCAUGUUUAACGA*C*A*cholesterol
asiTYR(17)-3 AS : UGUCGUUAAACAUGGGmU*mG*mU*mU*mG
asiTYR(17)-4 S : mCCmCAmUGmUUmUAmACmGA*mC*A*cholesterol
asiTYR(17)-4 AS : UGUCGUUAAACAUGGGU*G*U*U*G
asiTYR(17)-5 S : mCCmCAmUGmUUmUAmACmGA*mC*A*cholesterol
asiTYR(17)-5 AS : UGUCGUUAAACAUGGGU*G*mU*mU*mG
asiTYR(17)-6 S : mCCmCAmUGmUUmUAmACmGA*mC*A*cholesterol
asiTYR(17)-6 AS : UGUCGUUAAACAUGGGmU*mG*mU*mU*mG
asiTYR(44)-1 S : AGGUUCCUGUCAGA*A*U*cholesterol
asiTYR(44)-1 AS : AUUCUGACAGGAACCUC*U*G*C*C
asiTYR(44)-3 S : AGGUUCCUGUCAGA*A*U*cholesterol
asiTYR(44)-3 AS : AUUCUGACAGGAACCUmC*mU*mG*mC*mC
asiTYR(44)-4 S : mAGmGUmUCmCmGUmCAmGA*mA*U*cholesterol
asiTYR(44)-4 AS : AUUCUGACAGGAACCUC*U*G*C*C
asiTYR(44)-6 S : mAGmGUmUCmCmGUmCAmGA*mA*U*cholesterol
asiTYR(44)-6 AS : AUUCUGACAGGAACCUmC*mU*mG*mC*mC
asiTYR(45)-1 S : GGCAACUUCAUGGG*A*U*cholesterol
asiTYR(45)-1 AS : AUCCCAUGAAGUUGCCA*G*A*G*C
asiTYR(45)-3 S : GGCAACUUCAUGGG*A*U*cholesterol
asiTYR(45)-3 AS : AUCCCAUGAAGUUGCCmA*mG*mA*mG*mC
asiTYR(45)-4 S : mGGmCAmACmUUmCAmUGmGG*mA*U*cholesterol
asiTYR(45)-4 AS : AUCCCAUGAAGUUGCCA*G*A*G*C
asiTYR(45)-6 S : mGGmCAmACmUUmCAmUGmGG*mA*U*cholesterol
asiTYR(45)-6 AS : AUCCCAUGAAGUUGCCmA*mG*mA*mG*mC

MNT-1 cells (obtained from Sungkyunkwan University) were cultured in Minimum Essential Media (Welgene) containing 20% fetal bovine serum (Gibco), 100 µg/ml penicillin/streptomycin, 10% 200 mM HEPES (Welgene) and 10% Dulbecco's modified Eagle's medium (Welgene).

5 The potential cp-asiRNAs listed in Table 2 were incubated at 95 °C for 2 minutes and at 37 °C for 1 hour in OPTI-MEM buffer (Gibco). Proper strand annealing of the potential cp-asiRNAs was confirmed by gel electrophoresis.

One day prior to cp-asiRNA treatment, 2.0×10^4 cells were seeded 24 well plates. Immediately before treatment, the MNT-1 cells were washed with 1 x DPBS buffer (Gibco)
10 then cultured in the presence of the potential cp-asiRNAs in OPTI-MEM buffer for 24 hours, at which point the asiRNA-containing OPTI-MEM media was replaced with a serum-containing media. Twenty-four hours later, tyrosinase mRNA levels were in the MNT-1 cells were determined.

The level of tyrosinase inhibition by each of the 38 potential cp-asiRNAs is
15 provided in Figure 2. From among the potential cp-asiRNAs tested, cp-asiTYR(4)-1 was selected for further study.

Example 3: Inhibition of tyrosinase protein and melanin using tyrosine-specific cp-asiRNAs

The efficacy of cp-asiTYR(4)-1 for the inhibition of tyrosinase protein and the suppression of melanin production was tested. To test for non-specific effects, a mutated
20 cp-asiTYR that lacked sequence complementarity to the tyrosinase mRNA sequence (referred to as cp-asiTYR (seed mutation)) was also tested. The sequences of the cp-asiTYR (seed mutation) are provided in Table 3.

Table 3. Sequences used in cp-asiRNA(4)-1 (seed mutation) m = 2'-O-Methyl RNA. * = phosphorothioate bond.

cp-asiTYR(4)-1(seed mutation) S :	GCUGACAGGUCUAC*U*A*chol.
cp-asiTYR(4)-1(seed mutation) AS :	UAGUAGACCUGUCAGCU*U*C*U*G

The cp-asiRNA was incubated at 95 °C for 2 minutes and at 37 °C for 1 hour in OPTI-MEM buffer (Gibco). Proper strand annealing of the potential cp-asiRNAs was confirmed by gel electrophoresis.

30 MNT-1 cells were cultured in Minimum Essential Media (Welgene) containing 20% fetal bovine serum (Gibco), 100 µg/ml penicillin/streptomycin, 10% 200 mM HEPES (Welgene) and 10% Dulbecco's modified Eagle's medium (Welgene). One day prior to

treatment, 6.5×10^4 MNT-1 cells were seeded in 12-well plates. Immediately before treatment, the MNT-1 cells were washed with 1 x DPBS buffer (Gibco), and then cultured in the presence of 1 μ M or 3 μ M of cp-asiRNATYR(4)-1 in OPTI-MEM buffer for 24 hours, at which point the OPTI-MEM media was replaced with a serum-containing media.

5 After 72 hours of cp-asiTYR(4)-1 incubation, the level of tyrosinase protein expression was determined via western blot. Briefly, the treated MNT-1 cells were lysed with RIPA buffer (GE). Fifteen μ g of the total protein extract were loaded onto a 12% SDS-PAGE gel and electrophoresed at 120 V. After electrophoresis, the proteins were transferred to PVDF membrane (Bio-rad) already activated by methanol (Merck) for 1 hour
10 at 300 mA. The membrane was blocked for 1 hour at the room temperature with 5% skim milk (Seoul Milk) and then incubated overnight at 4°C in 5% skim milk containing anti-tyrosinase antibody (Santa Cruz) and anti- β -actin antibody (Santa Cruz). The membrane was then washed with 1x TBST for 10 minutes three times and was incubated for 1 hour at the room temperature in 5% skim milk with HRP-conjugated secondary antibody. The
15 membrane was washed with 1x TBST for 10 minutes and treated with 1x ECL for 1 minute. The tyrosinase and β -actin bands were then imaged using a Chemidoc instrument (Bio-rad).

The results of the western blot assay are depicted in Figure 3. As a result, in all cp-asiTYR #4-1 incubated cell lines, 70% or more of tyrosinase protein inhibition were confirmed. In addition, the cp-asiTYR was shown to have a higher efficiency in the
20 tyrosinase inhibition ability than other tyrosinase inhibitors such as Hydroquinone and Arbutin (Figure 3).

MNT-1 cells treated with cp-asiTYR(4)-1 as described above were tested for melanin content. After 72 hours of incubation in the presence of cp-asiTYR, the MNT-1 cells were collected, lysed with RIPA buffer (GE) and centrifuged at 13000 rpm. The
25 resulting melanin pellet was dissolved in 100 μ L of 1N NaOH (containing 10% DMSO) at 85 °C for 15 minutes and light absorption and melanin production were measured.

As shown in Figure 4, MNT-1 cells treated with 1 μ M cp-asiTYR(4)-1 showed greater than 60% inhibition in melanin production, which is higher than when treated with compounds commonly used for melanin production, including hydroquinone (20 μ M) and
30 arbutin (2 mM).

Example 4: MNT-1 cell lightening following treatment with cp-asiRNAs

The ability of cp-asiRNA(4)-1 to lighten the color of MNT-1 cells was tested.

As in Example 3, MNT-1 cells were cultured in the presence of 1 μ M or 3 μ M cp-asiTYR(4)-1. After 72 hours, cells were pelleted and the color change of the cells was observed. As shown in Figure 5, the color of the cp-asiTYR(4)-1 treated cells was lighter than untreated MNT-1 control cells (NT), hydroquinone treated cells and arbutin treated cells.

Example 5: Cytotoxicity of cp-asiRNAs

To test the cytotoxicity of cp-asiRNAs, MNT-1, a human melanoma cell line, and HaCaT, a human keratinocyte cell line were treated with cp-asiTYR #4-1 and hydroquinone.

The cp-asiRNA was incubated at 95 °C for 2 minutes and at 37 °C for 1 hour in OPTI-MEM buffer (Gibco). Proper strand annealing of the potential cp-asiRNAs was confirmed by gel electrophoresis.

One day before treatment with cp-asiRNA(4)-1, 5.0×10^3 MNT-1 cells or 1.0×10^4 HaCaT cells were seeded into 96 well plates. Immediately before treatment, the cells were washed with 1 x DPBS buffer (Gibco), and then cultured in the presence of 1 μ M or 3 μ M of cp-asiRNATYR(4)-1 in OPTI-MEM buffer for 24 hours, at which point the cytotoxicity level was measured using a CytoTox96 Non-Radio Cytotoxicity assay (Promega) according to manufacturer's instructions. The media was then replaced with the serum-containing media and cell viability was measured using a cell counting kit-8 (Enzo) according to manufacturer's instructions.

As shown in Figure 6, no cytotoxicity or loss of cell viability was observed in either MNT-1 or HaCaT due to treatment with cp-asiRNA. On the other hand, cytotoxicity was observed in HaCaT cells treated with hydroquinone or arbutin.

Example 6: Additional cp-asiRNA structures

A variety of potential cp-asiTYR structures having different strand lengths and numbers of 2'-O-methylation modifications were synthesized and tested for their ability to inhibit tyrosinase expression (Table 4).

Table 4. Additional cp-asiRNA sequences. m = 2'-O-Methyl RNA. * = phosphorothioate bond.

cp-asiTYR(4) S : GCUGACAGGAGAUG*A*A*cholesterol
cp-asiTYR(4) 21AS-1 : UUCAUCUCCUGUCAGCU*U*C*U*G
cp-asiTYR(4) 21AS-2 : UUCAUCUCCUGUCAGCU*U*mC*mU*mG
cp-asiTYR(4) 21AS-3 : UUCAUCUCCUGUCAGCmU*mU*mC*mU*mG
cp-asiTYR(4) 19AS-4 : UUCAUCUCCUGUCAG*C*U*U*C
cp-asiTYR(4) 19AS-5 : UUCAUCUCCUGUCAG*C*mU*mU*mC
cp-asiTYR(4) 19AS-6 : UUCAUCUCCUGUCAmG*mC*mU*mU*mC

The ability of 1 μ M of each of the potential cp-asiRNAs listed in Table 4 to inhibit tyrosinase mRNA in MNT-1 cells was tested.

MNT-1 cells were cultured in Minimum Essential Media (Welgene) containing 20% fetal bovine serum (Gibco), 100 μ g/ml penicillin/streptomycin, 10% 200mM HEPES (Welgene) and 10% Dulbecco's modified Eagle's medium (Welgene).

The potential cp-asiRNAs listed in Table 4 were incubated at 95 °C for 2 minutes and at 37 °C for 1 hour in OPTI-MEM buffer (Gibco). Proper strand annealing of the potential cp-asiRNAs was confirmed by gel electrophoresis.

One day prior to treatment, 2.0×10^4 MNT-1 cells were seeded in 24-well plates. Immediately before treatment, the MNT-1 cells were washed with 1 x DPBS buffer (Gibco) then cultured in the presence of the potential cp-asiRNAs in OPTI-MEM buffer for 24 hours, at which point the asiRNA-containing OPTI-MEM media was replaced with a serum-containing media. Twenty-four hours later, tyrosinase mRNA levels were in the MNT-1 cells were determined.

As seen in Figure 7, tyrosinase mRNA potential cp-asiRNAs containing 4 phosphorothioate bonds on 21 nucleotide antisense strands and potential cp-asiRNAs containing three 2'-O-Methylation and four phosphorothioate bonds on 19 nucleotide antisense strands exhibited the highest levels of tyrosinase inhibition. The cp-asiTYR(4) 21AS-1 and cp-asiTYR(4) 19AS-5 were selected for further experimentation.

The effect of cp-asiTYR(4) 21AS-1 and cp-asiTYR(4) 19AS-5 on the production tyrosinase protein and melanin production was tested.

The cp-asiRNA was incubated at 95 °C for 2 minutes and at 37 °C for 1 hour in OPTI-MEM buffer (Gibco). Proper strand annealing of the potential cp-asiRNAs was confirmed by gel electrophoresis.

MNT-1 cells were cultured in Minimum Essential Media (Welgene) containing 20% fetal bovine serum (Gibco), 100 µg/ml penicillin/streptomycin, 10% 200 mM HEPES (Welgene) and 10% Dulbecco's modified Eagle's medium (Welgene). One day prior to treatment, 6.5×10^4 MNT-1 cells were seeded in 12-well plates. Immediately before
5 treatment, the MNT-1 cells were washed with 1 x DPBS buffer (Gibco), and then cultured in the presence of 1 µM or 3 µM of cp-asiRNATYR(4)-1 in OPTI-MEM buffer for 24 hours, at which point the OPTI-MEM media was replaced with a serum-containing media.

The level of tyrosinase protein expression by MNT-1 cells after treatment with 1 µM and 3 µM cp-asiRNAs was determined via western blot. Briefly, the transfected MNT-
10 1 cells were lysed with RIPA buffer (GE). Fifteen µg of the total protein extract were loaded onto a 12% SDS-PAGE gel and electrophoresed at 120 V. After electrophoresis, the proteins were transferred to PVDF membrane (Bio-rad) already activated by methanol (Merck) for 1 hour at 300 mA. The membrane was blocked for 1 hour at the room
15 temperature with 5% skim milk (Seoul Milk) and then incubated overnight at 4°C in 5% skim milk containing anti-tyrosinase antibody (Santa Cruz) and anti-β-actin antibody (Santa Cruz). The membrane was then washed with 1x TBST for 10 minutes three times and was incubated for 1 hour at the room temperature in 5% skim milk with HRP-conjugated
secondary antibody. The membrane was washed with 1x TBST for 10 minutes and treated with 1x ECL for 1 minute. The tyrosinase and β-actin bands were then imaged using a
20 Chemidoc instrument (Bio-rad).

As seen in Figure 8, treatment with cp-asiTYR(4) 21AS-1 or cp-asiTYR(4) 19AS-5 resulted in a greater than 70% inhibition in the level of tyrosinase protein. In addition, with cp-asiTYR(4) 19AS-5 exhibiting a slightly higher inhibitory activity than cp-asiTYR(4) 21AS-1.

25 MNT-1 cells treated with cp-asiTYR(4) 21AS-1 or cp-asiTYR(4) 19AS-5 as described above were tested for melanin content. After 72 hours of incubation in the presence of cp-asiTYR, the MNT-1 cells were collected, lysed with RIPA buffer (GE) and centrifuged at 13000 rpm. The resulting melanin pellet was dissolved in 100 µL of 1N NaOH (containing 10% DMSO) at 85 °C for 15 minutes and light absorption and melanin
30 production were measured.

As shown in Figure 9, MNT-1 cells treated with 1 µM cp-asiTYR(4) 21AS-1 or cp-asiTYR(4) 19AS-5 showed about a 50% inhibition in melanin production, which is higher than the inhibition shown in MNT-1 cells treated with 2 mM arbutin.

Additional potential cp-asiTYR structures having different strand lengths, numbers of 2'-O-methylation modifications and numbers of phosphorothioate bond were synthesized and tested for their ability to inhibit tyrosinase expression (Table 5).

5 **Table 5. Additional cp-asiRNA sequences. m = 2'-O-Methyl RNA. * = phosphorothioate bond.**

cp-asiTYR(4) S : GCUGACAGGAGAUG*A*A*cholesterol
cp-asiTYR(4) 21AS-1 : UUCAUCUCCUGUCAGCU*U*C*U*G
cp-asiTYR(4) 19AS-7 : UUCAUCUCCUGUC*A*G*C*mU*mU*mC

The effect of cp-asiTYR(4) 21AS-1 and cp-asiTYR(4) 19AS-7 on the tyrosinase protein production was tested.

10 The cp-asiRNA was incubated at 95 °C for 2 minutes and at 37 °C for 1 hour in OPTI-MEM buffer (Gibco). Proper strand annealing of the potential cp-asiRNAs was confirmed by gel electrophoresis.

MNT-1 cells were cultured in Minimum Essential Media (Welgene) containing 20% fetal bovine serum (Gibco), 100 µg/ml penicillin/streptomycin, 10% 200 mM HEPES (Welgene) and 10% Dulbecco's modified Eagle's medium (Welgene). One day prior to treatment, 6.5 x 10⁴ MNT-1 cells were seeded in 12-well plates. Immediately before treatment, the MNT-1 cells were washed with 1 x DPBS buffer (Gibco), and then cultured in the presence of 1 µM, 0.6 µM, 0.3 µM and 0.1 µM of cp-asiTYR(4) 21AS-1 and cp-asiTYR(4) 19AS-7 in OPTI-MEM buffer for 24 hours, at which point the OPTI-MEM media was replaced with a serum-containing media.

The level of tyrosinase protein expression by MNT-1 cells after treatment with 1 µM, 0.6 µM, 0.3 µM and 0.1 µM cp-asiRNAs was determined via western blot. Briefly, the transfected MNT-1 cells were lysed with RIPA buffer (GE). Fifteen µg of the total protein extract were loaded onto a 12% SDS-PAGE gel and electrophoresed at 120 V. After electrophoresis, the proteins were transferred to PVDF membrane (Bio-rad) already activated by methanol (Merck) for 1 hour at 300 mA. The membrane was blocked for 1 hour at the room temperature with 5% skim milk (Seoul Milk) and then incubated overnight at 4°C in 5% skim milk containing anti-tyrosinase antibody (Santa Cruz) and anti-β-actin antibody (Santa Cruz). The membrane was then washed with 1x TBST for 10 minutes three times and was incubated for 1 hour at the room temperature in 5% skim milk with HRP-conjugated secondary antibody. The membrane was washed with 1x TBST for 10 minutes

and treated with 1x ECL for 1 minute. The tyrosinase and β -actin bands were then imaged using a Chemidoc instrument (Bio-rad).

As seen in Figure 10, treatment with cp-asiTYR(4) 21AS-1 or cp-asiTYR(4) 19AS-7 resulted in a greater than 70% inhibition in the level of tyrosinase protein. In addition, with cp-asiTYR(4) 21AS-1 exhibiting a slightly higher inhibitory activity than cp-asiTYR(4) 19AS-7.

Example 7: Use of cell penetrating peptide with asiRNAs and lasiRNAs

The combination of asiRNAs or lasiRNA with Pepfect 6 (PF6) cell penetrating peptide was tested for inhibition of tyrosinase mRNA and protein level without use of another transfection reagent.

asiTYR(4) and lasiTYR(21) (Table 6) were incubated at 95 °C for 2 minutes and at 37 °C for 1 hour in OPTI-MEM buffer (Gibco). Proper strand annealing of the asiRNA and lasiRNA was confirmed by gel electrophoresis. Annealed RNA and PF6 in DEPC was diluted in 100 μ l 0.6 x DPBS with a molar ratio of RNA complex:PF6 of 1:10 and then incubated at room temperature for 30 minutes for complex formation. Proper complex formation was confirmed by gel electrophoresis.

Table 6. Nucleic acid sequence of asiTYR(4) and lasiTYR(21).

asiTYR(4)S : GCUGACAGGAGAUGAA (SEQ ID NO: 7)
asiTYR(4)AS : UUCAUCUCCUGUCAGCUUCUG (SEQ ID NO: 8)
lasiTYR(21)S : GGUUCCUGUCAGAAUA (SEQ ID NO: 125)
lasiTYR(21)AS : UAUUCUGACAGGAACCUCUGCCUGAAAGCUG (SEQ ID NO: 126)

MNT-1 cells were cultured in Minimum Essential Media (Welgene) containing 20% fetal bovine serum (Gibco), 100 μ g/ml penicillin/streptomycin, 10% 200mM HEPES (Welgene) and 10% Dulbecco's modified Eagle's medium (Welgene). One day prior to treatment, 6.5 x 10⁴ MNT-1 cells were seeded in 12-well plates. Four hours prior to treatment, the cell media was replaced with 900 μ L of FBS-containing media. The PF6-complexed asiRNA or lasiRNA was added to the cells and the cells were incubated for 24 hours, at which point the media was replaced. Tyrosinase mRNA levels were measured using real-time RT-PCR 24 hours after media replacement.

As seen in Figure 11, MNT-1 cell lines treated with the PF6-complexed asiRNA or lasiRNA had significantly reduced levels of tyrosinase mRNA compared to control.

To test the treated MNT-1 cells for tyrosinase protein expression and melanin production, western blot and melanin content assays were performed as described above 48 hours after media replacement.

As seen in Figure 12, cell lines treated with asiTYR(4)/PF6 complex and lasiTYR(21)/PF6 complex exhibited at least 70% tyrosinase protein inhibition compared to control. Additionally, cells treated with asiTYR(4)/PF6 complex and lasiTYR(21)/PF6 complex exhibited less melanin production than control.

Example 8: Inhibition of melanin synthesis in reconstructed skin model using an exemplary cp-asiRNA

10 Tyrosinase expression and melanin level was analyzed in an cp-asiTYR#4-1 treated 3-D skin model. MEL-300-B (MatTek), a reconstructed skin model, was used in this study. MEL-300-B was stabilized in EPI-100-NMM-113 media 24 hours before treatment with cp-asiTYR#4-1. For annealing, cp-asiTYR#4-1 dissolved in DEPC-treated water was incubated at 95 °C for 2 minutes and at 37 °C for 1 hour. MEL-300-B samples were treated
15 with cp-asiTYR#4-1 every day for 13 days (final concentration = 5 µM) by adding cp-asiTYR#4-1 directly to the media. As a control, other MEL-300-B samples were treated with kojic acid (Sigma, 2% final) as depicted in Figure 14(a). The samples were harvested at day 14 and the melanocytes in the sample were analyzed using light microscopy. As seen in Figure 14(c), cp-asiTYR#4-1 treatment reduced the level of melanocytes in the treated
20 reconstructed skin model samples. Melanin level in each sample was analyzed using Fontana-Massons staining. As shown in Figure 14(c), ci-asiTYR#4-1 treatment reduced the level of melanin in the treated reconstructed skin model samples.

In order to analyze mRNA level at day 14, samples were harvested in Isol-RNA lysis reagent (5PRIME) and homogenized by using a homogenizer (IKA). Total RNA from
25 the each sample was extracted. For each sample, 500 ng of the extracted RNA was used for cDNA synthesis using the high-capacity cDNA reverse transcription kit (Applied Biosystems) according to the manufacturer's instructions. Quantitative real-time PCR was then performed using the StepOne real-time PCR system (Applied Biosystems). Amplification of the tyrosinase cDNA was detected using a power SYBR green PCR
30 master Mix (Applied Biosystems). GAPDH was amplified as an internal control. As shown in Figure 14(d), ci-asiTYR#4-1 treatment reduced the level of tyrosinase mRNA in the treated reconstructed skin model samples.

Protein level analysis was conducted as using western blot. Harvested samples in RIPA buffer (GE) were homogenized by using homogenizer (IKA) and protein from the each sample was obtained. Fifteen micrograms of the total protein extract were loaded onto a 12% SDS-PAGE gel and electrophoresed at 120 V. After electrophoresis, the proteins
5 were transferred to PVDF membrane (Bio-rad) that had been previously activated with methanol (Merck) for 1 hour at 300 mA. The membrane was blocked for 1 hour at the room temperature with 5% skim milk (Seoul Milk) and then incubated overnight at 4 °C in 5% skim milk containing anti-tyrosinase antibody (Santa Cruz) and anti-β-actin antibody (Santa Cruz). The membrane was then washed three times with 1x TBST for 10 minutes and was
10 incubated for 1 hour at the room temperature in 5% skim milk with HRP-conjugated secondary antibody. The membrane was washed with 1x TBST for 10 minutes and treated with 1x ECL (Thermo) for 1 minute. The tyrosinase and β-actin bands were then imaged using a Chemidoc instrument (Bio-rad). As shown in Figure 14e, potent knockdown of tyrosinase protein was observed in the cp-asiTYR#4-1 treated reconstructed skin model
15 sample.

To test melanin content, samples were harvested at day 14, lysed with RIPA buffer (GE) and centrifuged at 13000 rpm. The resulting pellet was dissolved in 100 μL of 1N NaOH (containing 10% DMSO) at 85 °C for 15 minutes and light absorption and melanin production were measured. As shown in Figure 14(f), cp-asiTYR#4-1 treatment reduced
20 melanin level in the treated reconstructed skin model samples.

Incorporation by Reference

All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication, patent or patent
25 application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention
30 described herein. Such equivalents are intended to be encompassed by the following claims.

What is claimed is:

1. An RNA complex comprising an antisense strand of at least 19 nucleotides (nt) in length having sequence complementarity to a tyrosinase mRNA sequence and a sense strand of 15 to 17 nt in length having sequence complementarity to the antisense strand, wherein the antisense strand and the sense strand form a complex in which the 5' end of the antisense strand and the 3' end of the sense strand form a blunt end.
2. The RNA complex of claim 1, wherein the antisense strand is 19 to 21 nt in length.
3. The RNA complex of claim 1, wherein the antisense strand is 19 nt in length.
4. The RNA complex of claim 1, wherein the antisense strand is 20 nt in length.
5. The RNA complex of claim 1, wherein the antisense strand is 21 nt in length.
6. The RNA complex of claim 1, wherein the antisense strand is at least 24 nt in length.
7. The RNA complex of claim 6, wherein the antisense strand is 24 to 121 nt in length.
8. The RNA complex of claim 1, wherein the antisense strand is 31 nt in length.
9. The RNA complex of any one of claims 1 to 8, wherein the sense strand is 15 nt in length.
10. The RNA complex of any one of claims 1 to 8, wherein the sense strand is 16 nt in length.
11. The RNA complex of any one of claims 1 to 8, wherein the sense strand is 17 nt in length.
12. The RNA complex of any one of claims 1 and 9 to 11, wherein the antisense strand has a sequence selected from the antisense strand sequences listed in Table 1, Table 2, Table 4 and Table 5.

13. The RNA complex of any one of claims claim 1 to 8 and claim 12, wherein the sense strand has a sequence selected from the sense strand sequences listed in Table 1, Table 2, Table 4, Table 5 and Table 6.
14. The RNA complex of claim 1, wherein the sense strand has a sequence of SEQ ID NO: 7 and the antisense strand has a sequence of SEQ ID NO: 8.
15. The RNA complex of claim 1, wherein the sense strand has a sequence of SEQ ID NO: 17 and the antisense strand has a sequence of SEQ ID NO: 18.
16. The RNA complex of claim 1, wherein the sense strand has a sequence of SEQ ID NO: 19 and the antisense strand has a sequence of SEQ ID NO: 20.
17. The RNA complex of claim 1, wherein the sense strand has a sequence of SEQ ID NO: 33 and the antisense strand has a sequence of SEQ ID NO: 34.
18. The RNA complex of claim 1, wherein the sense strand has a sequence of SEQ ID NO: 87 and the antisense strand has a sequence of SEQ ID NO: 88.
19. The RNA complex of claim 1, wherein the sense strand has a sequence of SEQ ID NO: 89 and the antisense strand has a sequence of SEQ ID NO: 90.
20. The RNA complex of claim 1, wherein the sense strand has a sequence of SEQ ID NO: 125 and the antisense strand has a sequence of SEQ ID NO: 126.
21. The RNA complex of any one of claims 1 to 20, wherein the RNA complex is capable of inhibiting tyrosinase expression by a cell.
22. The RNA complex of claim 21, wherein the cell is an A375 cell, an MNT-1 cell or a melanocyte.
23. The RNA complex of claim 22, wherein the cell is a melanocyte.
24. The RNA complex of any one of claims 1 to 23, wherein the RNA complex is capable of inhibiting melanin production by a cell.
25. The RNA complex of claim 24, wherein the cell is an MNT-1 cell or a melanocyte.

26. The RNA complex of any one of claims 1 to 25, wherein the RNA complex comprises a chemical modification.
27. The RNA complex of claim 26, wherein the RNA modification is a 2'-O-methylated nucleoside, a phosphorothioate bond or a cholesterol moiety.
28. The RNA complex of claim 27, wherein the RNA complex comprises a cholesterol moiety.
29. The RNA complex of claim 28, wherein the cholesterol moiety is attached to the 3' terminus of the sense strand.
30. The RNA complex of any one of claims 27 to 29, wherein the RNA complex comprises a 2'-O-methylated nucleoside.
31. The RNA complex of claim 30, wherein the 2'-O-methylated nucleoside is positioned at the 3' terminus of the sense strand.
32. The RNA complex of claim 30, wherein the 3' terminal region of the sense strand comprises a plurality of 2'-O-methylated nucleosides.
33. The RNA complex of claim 30, wherein the 2'-O-methylated nucleoside is positioned at the 3' terminus of the antisense strand.
34. The RNA complex of claim 30, wherein the 3' terminal region of the antisense strand comprises a plurality of 2'-O-methylated nucleosides.
35. The RNA complex of claim 30, wherein a 2'-O-methylated nucleoside is positioned at the 3' terminus of the sense strand and at the 3' terminus of the antisense strand.
36. The RNA complex of claim 30, wherein the 3' terminal region of the sense strand comprises a plurality of 2'-O-methylated nucleosides and the 3' terminal region of the antisense strand comprises a plurality of 2'-O-methylated nucleosides.
37. The RNA complex of any one of claims 27 to 36, wherein the RNA complex comprises a phosphorothioate bond.

38. The RNA complex of claim 37, wherein at least 25% of the bonds between the ribonucleotides in the sense strand of the RNA complex are phosphorothioate bonds.
39. The RNA complex of claim 37, wherein at least 50% of the bonds between the ribonucleotides in the sense strand of the RNA complex are phosphorothioate bonds.
40. The RNA complex of claim 37, wherein at least 75% of the bonds between the ribonucleotides in the sense strand of the RNA complex are phosphorothioate bonds.
41. The RNA complex of claim 37, wherein all of the bonds between the ribonucleotides in the sense strand of the RNA complex are phosphorothioate bonds.
42. The RNA complex of any one of claims 38 to 41, wherein at least 25% of the bonds between the ribonucleotides in the antisense strand of the RNA complex are phosphorothioate bonds.
43. The RNA complex of any one of claims 38 to 41, wherein at least 50% of the bonds between the ribonucleotides in the sense strand of the RNA complex are phosphorothioate bonds.
44. The RNA complex of any one of claims 38 to 41, wherein at least 75% of the bonds between the ribonucleotides in the sense strand of the RNA complex are phosphorothioate bonds.
45. The RNA complex of any one of claims 38 to 41, wherein all of the bonds between the ribonucleotides in the sense strand of the RNA complex are phosphorothioate bonds.
46. The RNA complex of claim 26, wherein the RNA complex is a modified RNA complex listed in Table 2, Table 4 or Table 5.
47. The RNA complex of any one of claims 26 to 46, wherein the RNA complex is capable of penetrating the cellular membrane of a cell in the absence of a delivery vehicle.
48. The RNA complex of claim 47, wherein the cell is an A375 cell, an MNT-1 cell or a melanocyte.

49. The RNA complex of any one of claims 1 to 48, wherein the RNA complex is not cytotoxic.
50. A method of inhibiting tyrosinase expression by a cell comprising contacting the cell with an RNA complex of any one of claims 1 to 49.
51. The method of claim 50, wherein the cell is a melanocyte.
52. The method of claim 50 or 51, wherein the cell is present in the skin of a human subject.
53. A method of inhibiting melanin production by a cell comprising contacting the cell with an RNA complex of any one of claims 1 to 49.
54. The method of claim 53, wherein the cell is a melanocyte.
55. The method of claim 53 or 54, wherein the cell is present in the skin of a human subject.
56. A method of reducing melanin production in the skin of a subject comprising administering to the subject an RNA complex of any one of claims 1 to 49.
57. The method of claim 56, wherein the subject has a skin pigmentation disorder associated with excessive melanin production.
58. The method of claim 57, wherein the skin pigmentation disorder is melasma or age spots.
59. The method of any one of claims 56 to 58, comprising topically administering the RNA complex to the skin of the subject.
60. The method of any one of claims 56 to 59, wherein the subject self-administers the RNA complex.
61. The method of any one of claims 56 to 60, further comprising administering to the subject a second skin lightening agent.

62. The method of claim 61, wherein the second skin lightening agent is selected from hydroquinone, arbutin, tretinoin, kojic acid, azelaic acid and tranexamic acid.
63. A method of treating a skin pigmentation disorder associated with excessive melanin production in a subject comprising administering to the subject an RNA complex of any one of claims 1 to 49.
64. The method of claim 63, wherein the skin pigmentation disorder is melasma or age spots.
65. The method of any one of claims 63 to 64, comprising topically administering the RNA complex to the skin of the subject.
66. The method of any one of claims 63 to 65, wherein the subject self-administers the RNA complex.
67. The method of any one of claims 63 to 66, further comprising administering to the subject a second skin lightening agent.
68. The method of claim 67, wherein the second skin lightening agent is selected from hydroquinone, arbutin, tretinoin, kojic acid, azelaic acid and tranexamic acid.
69. A pharmaceutical composition comprising an RNA complex of any one of claims 1 to 49 and a pharmaceutically acceptable carrier.
70. The pharmaceutical composition of claim 69, wherein the composition is formulated for topical delivery.
71. The pharmaceutical composition of claim 70, wherein the pharmaceutical composition is a cream or a lotion.
72. The pharmaceutical composition of any one of claims 69 to 71, wherein the pharmaceutical composition further comprises a second skin lightening agent.
73. The pharmaceutical composition of claim 72, wherein the second skin lightening agent is selected from hydroquinone, arbutin, tretinoin, kojic acid, azelaic acid and tranexamic acid.

74. A method of reducing melanin production in the skin of a subject comprising administering to the subject a pharmaceutical composition of any one of claims 69 to 73.

75. The method of claim 74, wherein the subject has a skin pigmentation disorder associated with excessive melanin production.

76. The method of claim 75, wherein the skin pigmentation disorder is melasma or age spots.

77. The method of any one of claims 74 to 76, comprising topically administering the pharmaceutical composition to the skin of the subject.

78. The method of any one of claims 74 to 77, wherein the subject self-administers the pharmaceutical composition.

79. A method of treating a skin pigmentation disorder associated with excessive melanin production in a subject comprising administering to the subject a pharmaceutical composition of any one of claims 69 to 73.

80. The method of claim 79, wherein the skin pigmentation disorder is melasma or age spots.

81. The method of any one of claims 79 to 80, comprising topically administering the pharmaceutical composition to the skin of the subject.

82. The method of any one of claims 79 to 81, wherein the subject self-administers the pharmaceutical composition.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11





Figure 12






Figure 13

Human Tyrosinase mRNA sequence.


```

1   atcactgtag tagtagctgg aaagagaaat ctgtgactcc aattagccag ttctgcaga
61  ccttgtgagg actagaggaa gaatgctcct ggctgttttg tactgcctgc tgtggagttt
121 ccagacctcc gctggccatt tccctagagc ctgtgtctcc tctaagaacc tgatggagaa
181 ggaatgctgt ccaccgtgga gcggggacag gagtccctgt ggccagcttt caggcagagg
241 ttctgtcag aatatccttc tgtccaatgc accacttggg cctcaatttc ccttcacagg
301 ggtggatgac cgggagtcgt ggccttcctt cttttataat aggacctgcc agtgctctgg
361 caacttcatg ggattcaact gtggaaactg caagtttggc ttttggggac caaactgcac
421 agagagacga ctcttggatg gaagaaacat cttcgatttg agtgccccag agaaggacaa
481 attttttgcc tacctcactt tagcaaagca taccatcagc tcagactatg tcatcccat
541 agggacctat ggccaaatga aaaatggatc aacacccatg tttaacgaca tcaatattta
601 tgacctcttt gtctggatgc attattatgt gtcaatggat gcactgcttg ggggatctga
661 aatctggaga gacattgatt ttgcccatag agcaccagct tttctgcctt ggcatagact
721 cttcttggtt cgggtgggaac aagaaatcca gaagctgaca ggagatgaaa acttcactat
781 tccatatttg gactggcggg atgcagaaaa gtgtgacatt tgcacagatg agtacatggg
841 aggtcagcac ccacaaaatc ctaacttact cagcccagca tcattctctt cctcttggca
901 gattgtctgt agccgatttg aggagtacaa cagccatcag tctttatgca atggaacgcc
961 cgagggacct ttacggcgta atcctggaaa ccatgacaaa tccagaaccc caaggctccc
1021 ctcttcagct gatgtagaat tttgcctgag tttgacccaa tatgaatctg gttccatgga
1081 taaagctgcc aatttcagct ttagaaatac actggaagga tttgctagtc cacttactgg
1141 gatagcggat gcctctcaaa gcagcatgca caatgccttg cacatctata tgaatggaac
1201 aatgtcccag gtacagggat ctgccaacga tcctatcttc cttcttcacc atgcatttgt
1261 tgacagtatt tttgagcagt ggctccgaag gcaccgtcct cttcaagaag tttatccaga
1321 agccaatgca ccatttggac ataaccggga atcctacatg gttcctttta taccactgta
1381 cagaaatggg gatttcttta tttcatccaa agatctgggc tatgactata gctatctaca
1441 agattcagac ccagactctt ttcaagacta cattaagtcc tatttggaa aagcgagtcg
1501 gatctggtca tggctccttg gggcggcgat ggtagggggc gtccctcactg cctgctggc
1561 agggcttggt agcttgctgt gtcgtcacaa gagaaagcag cttcctgaag aaaagcagcc
1621 actcctcatg gagaaagagg attaccacag cttgtatcag agccatttat aaaaggctta
1681 ggcaatagag tagggccaaa aagcctgacc tactctaac tcaaagtaat gtccaggttc
1741 ccagagaata tctgctggta ttttctgtga aagaccattt gcaaaattgt aacctaatac
1801 aaagtgtagc cttcttccaa cttaggtaga acacacctgt ctttgtcttg ctgttttcac
1861 tcagcccttt taacattttc ccctaagccc atatgtctaa ggaaaggatg ctatttggta
1921 atgaggaact gttatttgta tgtgaattaa agtgctctta ttttaaaaaa ttgaaataat
1981 tttgattttt gccttctgat tatttaaaaga tctatatatg ttttattggc cccttcttta
2041 ttttaataaa acagtgagaa atctaaaaaaa aaaaaaaaaa aa


```

Figure 14


(a)




(b)




(c)




(d)



(e)



(f)



INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2016/001169**A. CLASSIFICATION OF SUBJECT MATTER****C12N 15/113(2010.01)i, A61K 31/7105(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12N 15/113; C07H 21/02; C12N 15/11; A61K 48/00; A61K 31/7105

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords:asiRNA, tyrosinase, sense strand, antisense strand

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KR 10-1207561 B1 (COREANA COSMETICS CO., LTD.) 04 December 2012 See abstract; claim 1; paragraphs [0032]-[0033]; table 1.	1-11
A		14-20
Y	US 2013-0273657 A1 (LEE, DONG KI) 17 October 2013 See abstract; claim 1; paragraph [0068]; figure 3.	1-11
A	US 8822428 B2 (L'OREAL) 02 September 2014 See abstract; claim 1.	1-11, 14-20
A	CN 102719432 A (NANJING UNIVERSITY) 10 October 2012 See abstract; claims 1-4.	1-11, 14-20
A	CHANG, CHAN IL et al., 'Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects', Molecular Therapy, April 2009, Vol. 17, No. 4, pp. 725-732 See the whole document.	1-11, 14-20
A	JO, SEUL-GI et al., 'Selection and optimization of asymmetric siRNA targeting the human c-MET gene', Molecules and Cells, 31 December 2011, Vol. 32, pp. 543-548 See the whole document.	1-11, 14-20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

25 October 2016 (25.10.2016)

Date of mailing of the international search report

26 October 2016 (26.10.2016)

Name and mailing address of the ISA/KR

International Application Division

Korean Intellectual Property Office


189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea

Facsimile No. +82-42-481-8578

Authorized officer

HEO, Joo Hyung

Telephone No. +82-42-481-8150



Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 50-68,74-82
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 50-68 and 74-82 pertain to a method for treatment of the human body by therapy, and thus relate to a subject matter which this International Searching Authority is not required, under PCT Article 17(2)(a)(i) and PCT Rule 39.1(iv), to search.
2. ☒ Claims Nos.: 22-23,25,27-29,31-36,38-41,46,48,51,54,57-58,62,64,68,70-71,73,75-76,80
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims 22-23, 25, 27-29, 31-36, 38-41, 46, 48, 51, 54, 57-58, 62, 64, 68, 70-71, 73, 75-76 and 80 are unclear since they are referring to the multiple dependent claims which do not comply with PCT Rule 6.4(a).
3. ☒ Claims Nos.: see Extra Sheet
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of any additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/IB2016/001169

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
KR 10-1207561 B1	04/12/2012	KR 10-2011-0068061 A	22/06/2011
US 2013-0273657 A1	17/10/2013	CA 2818662 A1	26/04/2012
		CN 103328633 A	25/09/2013
		EP 2631291 A2	28/08/2013
		EP 2631291 A4	14/01/2015
		JP 2013-544505 A	19/12/2013
		JP 5795072 B2	14/10/2015
		KR 10-1328568 B1	13/11/2013
		KR 10-2012-0042645 A	03/05/2012
		WO 2012-053741 A2	26/04/2012
		WO 2012-053741 A3	14/06/2012
		WO 2012-053741 A9	02/08/2012
US 8822428 B2	02/09/2014	CN 102579274 A	18/07/2012
		CN 102579274 B	27/04/2016
		CN 105854028 A	17/08/2016
		CN 1966084 A	23/05/2007
		EP 1774959 A1	18/04/2007
		FR 2890859 A1	23/03/2007
		FR 2890859 B1	21/12/2012
		JP 2007-084544 A	05/04/2007
		JP 2013-255511 A	26/12/2013
		JP 5390065 B2	15/01/2014
		JP 5951564 B2	13/07/2016
		KR 10-0865061 B1	23/10/2008
		KR 10-1215340 B1	26/12/2012
		KR 10-1307734 B1	11/09/2013
		KR 10-2007-0033284 A	26/03/2007
		KR 10-2008-0076885 A	20/08/2008
		KR 10-2009-0118889 A	18/11/2009
		US 2007-0134188 A1	14/06/2007
		US 2009-0081263 A1	26/03/2009
		US 2013-0195966 A1	01/08/2013
		US 8410260 B2	02/04/2013
CN 102719432 A	10/10/2012	CN 102719432 B	23/10/2013

(Continuation of BOX No. II)

Item No. 3: Claims Nos. 12-13, 21, 24, 26, 30, 37, 42-45, 47, 49-50, 52-53, 55-56, 59-61, 63,
65-67, 69, 72, 74, 77-79 and 81-82.